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Abstract 
Shah, Ekta J, M.S. Department of Pharmacology and Toxicology, Wright State  
University, 2014. Effect of Q-VD-OPh on Neurodegeneration and Neuroinflammation of 
Sarin Exposed Mice 
 
 
Organophosphates (OP) cause CNS hyperstimulation resulting in seizures, convulsions 
and brain damage. Sarin is a toxic nerve agent used in Syria, the Gulf War and in terrorist 
attacks in Japan. Exposure to sarin is associated with presence of dead neurons, activation 
of astrocytes, microglia and neuroinflammation. Since, cell death and neuroinflammation 
are found in sarin exposed animals, we evaluated the efficacy of Q-VD-OPh, a broad 
spectrum caspase inhibitor that prevents cell death and has anti-inflammatory properties. 
Currently, treatment for sarin exposures is effective only if administered within 30-40 
minutes of exposure. In this study, adult female C57BL/6 mice were subjected to an 
injection of 1.5 mg/kg CBDP before a 0.04mg/kg injection of sarin followed by 20 mg/kg 
injection of Q-VD-OPh 30 minutes later. Mice were sacrificed at two and fourteen day 
time points followed by cytokine analysis of amygdala and hippocampus using Bio-Plex 
200 Pro Mouse Cytokine Grp I Panel (23-Plex) kit. We found a significant increase in 13 
out of 23 examined cytokines in amygdala after 2 days of sarin exposure. Also, sarin 
elicits a strong response in amygdala and hippocampus. After treatment with Q-VD-OPh, 
the cytokines did not change appreciably between 2 and 14 days in the sarin/Q-VD-OPh 
treated animals. Q-VE-OPh, a negative control for Q-VD-OPh was used and it showed no 
 
iv 
 
significant change at the two or fourteen day time points in amygdala and hippocampus. 
To detect DNA fragmentation, 12μm thick sections were TUNEL-stained using 
NeuroTacs Apoptosis kit. Q-VD-OPh effect on cholinesterase activity was detected by 
ChE assay. Frontal cortex was used to analyse apoptosis markers and for cholinesterase 
activity. TUNEL staining was increased in sarin treated sections but was seen to be less 
in sections treated with Q-VD-OPh at 2 days. At 14 days, there was not much difference 
seen. Also, Q-VE-OPh showed intense staining as compared to Q-VD-OPh. ChE assay 
showed that Q-VD-OPh did not appear to have an inhibitory effect in mice treated with it 
and sarin. These trends may be indicative of Q-VD-OPh being effective in attenuating 
neurodegeneration and neuroinflammation in sarin exposed mice.  
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Introduction 
Chemical warfare agents (CWA) are chemical substances with toxic properties that can 
kill, injure or incapacitate an enemy and associated military operations (Chauhan et al., 
2008). Most widely known compounds of this category are nerve agents, a class of 
compounds developed as chemical warfare weapons. They are extremely potent 
inhibitors of the enzyme acetylcholinesterase, a key regulator of cholinergic 
neurotransmission (Geoghegan & Tong, 2006). So far, the best-known nerve agents are 
organophosphate (OP) compounds that share similarity in chemical structure to 
organophosphate insecticides. Nerve agents can be inhaled or absorbed through skin and 
the time of onset of intoxication can vary with the dose and route of exposure. Onset of 
hyper secretion, loss of consciousness, tremors and convulsions can occur within a 
minute of exposure, however, symptoms may worsen to respiratory arrest within 5 
minutes post inhalation (Dunn, 1989). Figure 1 shows the general structure of 
organophosphates. OP’s can be classified as G and V agents. G series include Tabun or 
GA (ethyl N,Ndimethylphosphoramidocyanidate), Sarin or GB (isopropyl 
methylphosphonofluoridate), Soman or GD (O-Pinacolyl methylphosphonofluoridate), 
Cyclosarin or GF (cyclohexyl methylphosphonofluoridate) and V series include VX (O-
ethyl-S-2 diisopropylaminoethylmethylphosphonothioate). The GV-series nerve agents 
combine the properties of both classes. In general, G series agents have lesser persistency 
(ability to sustain in the environment) and potency than V series agents (Figure 2). 
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Figure 1: General Structure of Nerve Agents. The generic structure for all OPs is the 
same with a central P and three R groups that can be modified. R can be replaced by (-F), 
(-CN) in case of G-series agents or with  (SCH2 CH2N[CH(CH3)2]2) in case of V-series 
agents (Augerson, 1998). 
  
  
 Fig 2: G and V series nerve agents . G series includes sarin, soman, tabun and 
cyclosarin whereas V series agents are VX, VG and sulfar mustard (Sambrook & 
Notman, 2013). 
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Global Effect of Sarin exposure 
Sarin, also called GB, is an extremely toxic nerve agent produced for the very first time 
in Germany in 1937 as an insecticide. Being a very powerful inhibitor of cholinesterase, 
its potential as a battlefield weapon was soon recognized. Germany produced thousands 
of tons of tabun and sarin during WWII but abstained from using them. In the early 
1950s, sarin was produced for military purposes by both the USSR and the USA after it 
was designated as a chemical weapon by NATO (Vale, Marrs, & Rice, 2012). The 1980 
Iran-Iraq conflict marks the onset of use of sarin in wars. In April 1988, towards the end 
of the Iran-Iraq conflict, sarin was used four times against Iranian soldiers (Wiener and 
Hoffman, 2004). In June 1994, members of the Aun Shinrikyo cult released sarin in 
Matsumoto killing 7 and injuring over 200 people (Bricker, 2004). In March 1995, on the 
day of the Tokyo subway attack underneath the Japanese National Government’s 
ministry offices in Tokyo more than 5,000 passengers and crew members in the subway 
experienced lethal exposure to sarin gas injuring most of them and killing 12. Both these 
lethal nerve gas attacks led to the deaths of 19 people, as well as to a large number of 
injuries (Seto, 2001). In May 2004, sarin was detected in the wreckage of a bomb 
explosion in Iraq (Abu-Qare & Abou-Donia, 2002). UN investigators found convincing 
evidence of sarin being used in an attack in the Ghouta region of the Rif Dimashq 
Governorate of Syria during the Syrian civil war on August 21 2013 that killed hundreds 
of people. 
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Table 1: History of Sarin 
Year Event 
1938  
Discovered in Wuppertal-Elberfeld in Germany by scientists at IG 
Farben attempting to create stronger pesticides 
1950s 
(early) 
 NATO adopted sarin as a standard chemical weapon, and both the USSR and 
the United States produced sarin for military purposes. 
1956 
Regular production of sarin ceased in the United States, though existing stocks 
of bulk sarin were re-distilled until 1970 
1988 
 Sarin was included in the Halabja poison gas attack, killing approximately 
5,000 people  
1993 
The United Nations Chemical Weapons Convention was signed by 162 
member countries, banning the production and stockpiling of many chemical 
weapons, including sarin 
1994 
 The Japanese religious sect Aum Shinrikyo released an impure form of sarin 
in Matsumoto, Nagano 
1995  Aum Shinrikyo sect released an impure form of sarin in the Tokyo Metro 
2004 
 Iraqi insurgents detonated a 155 mm shell containing binary precursors for 
sarin near a U.S. convoy in Iraq 
2013 
Sarin was used in an attack in the Ghouta region of the Rif 
Dimashq Governorate of Syria during the Syrian civil war 
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Sarin: Structure, Properties and Pharmacokinetics 
Sarin (Isopropyl methylphosphonofluoridate), the high potency OP ester is a clear, 
odorless gas that civilians can be exposed to either through inhalation or in liquid form. 
Figure 3 shows the structure of sarin. 
    
                                               
Fig 3: Structure of Sarin (Isopropyl methylphosphonofluoridate) with the formula 
[(CH3)2CHO]CH3P(O)F.  
 
With a vapor pressure of 2.1mm Hg at 20°C and volatility of 16,400-22,000 mg/m3 at 
25°C, sarin is the most volatile of all nerve agents. Because it has a vapor pressure 
similar to water it is also called a ‘nerve gas’. As a liquid, sarin can easily penetrate skin 
and clothing, while as a vapor it can rapidly enter the mucous membrane of the eye or be 
inhaled into the lungs, where it is quickly absorbed. Sarin is rapidly distributed in the 
gastrointestinal tract and crosses the skin barrier and eyes (Chauhan et al., 2008). Sarin 
can remain persistent in the environment after deployment for 2-24 hours at 5-25°C. 
Sarin is metabolized after administration in animals or humans, urine being the major 
route of excretion of sarin metabolite isopropyl methylphosphonic acid. (Wiener & 
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Hoffman, 2004). Peak levels of sarin metabolite were found in human urine about 10-18 
hours following Tokyo subway attack (Hui & Minami, 2000). Little et al. (1986) found 
that following an 80 mg/kg IV dose in mice, sarin was detected in the heart, lung and 
brain within a minute, with the highest concentrations being in kidneys, liver and plasma. 
A subcutaneous dose of 75mg/kg of sarin in rats showed that urine was the major route of 
excretion of sarin metabolite isopropyl methylphosphonic acid with a half-life in urine of 
3.7 hours ((Shih & McDonough, 1999). 
 
Sarin: Mechanism of Action 
Acetylcholine (ACh) is a neurotransmitter that is active in the central nervous system 
(CNS) and at neuromuscular junctions throughout the peripheral nervous system (PNS).  
When released from a pre-synaptic nerve terminal presynaptic storage vesicles exocytose 
ACh into the cleft where it binds receptors, is quickly released, and then hydrolyzed by 
acetylcholinesterase (AChE) into acetate and choline (Figure 4A).This effectively 
inactivates the neurotransmitter and terminates the signal transmission. Sarin irreversibly 
inhibits AChE, the enzyme responsible for degrading acetylcholine (ACh).  The 
mechanism for this action is sarin binding to the serine residue within the active motif 
(active motif has histidine, glutamate and serine residues) of AChE (Figure 4B).Once 
bound, sarin is de-acylated leaving behind a phosphate group that cannot be removed, 
and the resultant inactive enzyme (Figure 4C).If treated within 30-40 minutes of 
exposure, the bond formation can be reversed. After this duration the bond becomes 
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stable and the enzyme is said to have ‘aged’.When AChE is inhibited, as in the case of 
OP poisoning, the ACh remains at the nerve terminal continuously eliciting a response 
from the post-synaptic nerve.  Seizures, convulsions, and brain damage resembling status 
epilepticus (a state of continuous seizures) occur as a result of this hyper-stimulation 
which has been strongly associated with brain damage in survivors, and death (Davidson, 
2007; Hoskins et al., 1986). 
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Fig 4: Mechanism of Action of Sarin A) Interaction between ACh and AChE: ACh is 
broken down into acetic acid and choline by enzyme AChE and thus terminates signal 
transmission B) Nucleophilic interaction between nerve agent and AChE: Nerve agent 
binds to the serine residue in the active site of enzyme and interact with the serine 
hydroxyl residue blocking the site from action of ACh C) The ‘aged’ enzyme: Over time, 
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a functional group leaves the enzyme making the bond permanent. (Adapted from Wiener 
& Hoffman, 2004). 
 
Signs, Symptoms and Chronic effects of Sarin exposure 
Following local exposure there is systemic absorption causing inhibition of AChE 
in the eye and upper and lower respiratory tract. This leads to miosis, nasal hyperemia, 
frontal headache, dimness of vision, nausea and vomiting. Respiratory effects include 
tightness in chest, and occasionally found to be coupled with prolonged wheezing leading 
to death suggestive of bronchoconstriction (Moshiri, Darchini-Maragheh, & Balali-
Mood, 2012). 
Convulsive properties of sarin exposure are thought to be due to reduction in the 
levels of γ-aminobutyric acid, an inhibitory neurotransmitter. Nerve agents bind to 
musacarininc and glutamate NMDA receptors and antagonize GABA 
neurotransmission(Geoghegan & Tong, 2006). Thus, sarin may act as a muscarinic 
receptor antagonist. Muscarinic signs and symptoms include pinpoint pupils, blurred or 
dimmed vision, rhinorrhea, headache, hypersecretion by salivary, lacrimal, sweat, and 
bronchial glands, nausea, vomiting, diarrhea, crampy abdominal pain, bowel and bladder 
incontinence and dyspnea.  
Increased fatigability, generalized weakness, muscular twitching, respiratory 
distress due to weakness in muscles of respiration, fasciculation’s usually appearing in 
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the eyelids, facial and calf muscles and mild to moderate increase in blood pressure occur 
because of nicotinic receptor stimulation due to sarin (Dunn, 1989). 
 Figure 5 shows primary and secondary targets of organophosphate exposure along 
with the effects of such exposures. Early exposure symptoms include tension, jitteriness, 
restlessness, anxiety, giddiness and emotional lability. Extensive exposure results in 
tremors, drowsiness, slowness of recall, mental confusion, headache and difficulty in 
concentration. If the dose is sufficient, death results after respiratory failure (Grob & 
Harvey, 1953; Lee, 2013). 
 
Fig 5: The figure shows primary and secondary targets of organophosphates. Primary 
target being AChE and several secondary targets including serine hydrolases. In addition, 
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the outer circle shows the effects of OP exposure like collateral damage, 
neurodegeneration, neuroinflammation, delayed neurotoxicity etc. 
Abbreviations: AFMID, arylformamidase; CB1, cannabinoid CB1 receptor; FAAH, fatty 
acid amide hydrolase; NTE, neuropathy target esterase; LysoPLA, lysophospholipase; 
APH, acylpeptide hydrolase; AChE, acetylcholinesterase; GI, Gastrointestinal. 
 
Moreover, common mnemonics for the symptomatology of organophosphate 
poisoning, including sarin gas, are the "killer B's" of bronchorrhea and bronchospasm 
because they are the leading cause of death and SLUDGE - Salivation, Lacrimation, 
Urination, Defecation, Gastrointestinal distress, and Emesis (Leon, 2005). 
Figure 6 shows a chart of effects of organophosphate exposure based on the type of 
receptor stimulted 
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Fig 6: Shows signs and symptoms of sarin exposure based on the type of cholinergic 
receptor stimulated, muscarinic effects, nicotinic effects and general CNS effects. 
(Adapted from Grob & Harvey, 1953).  
 
Neurodegeneration and Neuroinflammation following OP exposure 
Tanaka et. al., found that exposure to sarin induces seizures progressing to status 
epilepticus and prolonged status epilepticus has been linked to cell death and cell injury 
in brain (1996).  
In a study carried out by Henderson et. al. (2002) to investigate the response of 
rats to low level exposure of sarin, it was found that brain mRNA for IL-1β, TNF-α and 
IL-6 was increased in a dose dependent manner. Williams et. al. (2003), studied the three 
brain regions namely thalamus, hippocampus and piriform cortex and found a 20 to 550 
fold increase in the levels of IL-6, IL-1β and TNF-α between 2-6 hrs post soman 
exposure. Chapman, Kadar, & Gilat, 2006) investigated the alterations in 
neuroinflammatory markers in conjunction with length of sarin-induced seizure activity 
in rat brains following sarin exposure. They found an increase in pro-inflammatory 
cytokines IL-1β, IL-6 and TNF-α following 2 hrs of sarin exposure with increase in levels 
of PGE2 after 6 hrs. They also showed that early treatment with an anti-epileptic drug, 
i.e., midazolam, helps to decrease the level of cytokines in a time dependent manner . 
Based on these studies, it can thus be inferred that exposure to sarin and 
other such OP’s appears to be associated with neuroinflammation. 
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Cell Death  
Following sarin exposure, mainly two types of neuronal death can occur : necrosis 
and apoptosis (Bricker, 2004). Physiological or pathological changes trigger an 
upregulation in mitochondrial permeability. Mitochondria has the control to decide 
whether the cell will commit suicide or proceed towards survival after experiencing stress 
or damage. In response to these changes, mitochondria releases a number of proteins that 
can initiate a cascade of events leading to cell death.  
Necrosis vs Apoptosis 
Figure 7 depicts a diagrammatic representation of the differences between the two main 
types of cell death: Apoptosis and Necrosis. 
 Necrosis is a process of accidental and premature cell death caused by factors external to 
cell or tissue such as infection, toxins or trauma. Necrosis is the end result of 
bioenergetics catastrophe arising from ATP depletion to a level incompatible with cell 
survival. It is signaled by irreversible changes in the nucleus and is seen by disruption of 
plasma membrane, swelling of cells, destruction of cellular structure and an induction of 
inflammation around the dying cell due to release of cellular contents (Edinger & 
Thompson, 2004; Krysko, Vanden Berghe, D’Herde, & Vandenabeele, 2008). The key 
features to distinguish apoptosis from necrosis is the involvement of enzymatic 
machinery namely caspase activation and formation of DNA fragments ~200 bp in case 
of apoptosis (Fink & Cookson, 2005). Accidental or immediate cell death mainly 
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involves large groups of cells while apoptosis involves single cells that undergo 
programmed death.  
Apoptosis is a programmed cell death starting with a death signal that may or may 
not be expected. Thus, some condition, e.g., toxins, may cause apoptosis that is termed 
inappropriate cell death. In order for cell death to be classified as apoptotic, nuclear 
condensation, nuclear blebbing, cleavage of chromosomal DNA and packing of cell 
debris into apoptotic bodies must be observed (Edinger & Thompson, 2004). In execution 
of apoptosis, proteolytic enzymes and caspases are activated. These caspases in turn 
generate a cascade of apoptotic proteinases. Eventually, there is activation of caspase 
activated DNase (CAD) leading to DNA laddering, a characteristic of apoptosis. At the 
end, small apoptotic bodies are formed that are cleared by phagocytosis (Kerr, Wyllie, & 
Currie, 1972). Necrosis is characterized by the absence of caspases and DNA laddering, 
however, in the absence of phagocytosis, apoptotic bodies turn into secondary or 
apoptotic  necrosis (i.e. dead cells that have reached this state via the apoptotic program) 
with morphology similar to primary necrosis. While, in some situations, necrotic bodies 
display chromosomal condensation and other features of apoptotis (Majno & Joris, 1995). 
Presence of necrosis indicates cell death but not necessarily how cell death has occurred 
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(Fink & Cookson, 2005)
  
Fig 7: Apoptosis Vs Necrosis  
Apoptois is mainly characterized by chromatin condensation whereas necrosis involves 
cell swelling (Adapted from Van Cruchten & Van den Broeck, 2002). 
 
Mitochondria and Apoptosis 
Mitochondria are responsible for ‘deciding’ whether a cell undergoes apoptosis or 
necrosis. One of the most important classes of apoptosis regulating genes is the Bcl-2 
family of proteins. The Bcl-2 family of proteins is directly associated to the actions that 
can increase the mitochondrial permeability and hence the outflow of apoptotic proteins. 
The Bcl-2 family encompasses both pro and anti-apoptotic proteins. The relative 
proportions of these proteins decides the fate of the cell. (Fink & Cookson, 2005; 
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Kroemer, Dallaporta, & Resche-Rigon, 1998). Nevertheless, further exploration is 
necessary in order to determine what mode of cell death occurs in response to nerve gas 
exposure. Many but not all Bcl-2 proteins reside on the mitochondrial membrane. The 
Bcl-2 family consists of proteins that can be divided into either death antagonists (Bcl-
XL, Bcl-w, Bcl-2) or death agonists (Bad, Bax, Bcl-XS, Bak) (Kroemer et al., 1998; 
Wang & Youle, 2009). The susceptibility to apoptosis is determined by the relationship 
between pro and anti-apoptotic factors. If the level of pro-apoptotic factors surpasses that 
of anti-apoptotic factors, mitochondria release a number of apoptosis promoting factors 
(Mi & Kivuo, 2002; Tanaka et al., 1996).  
 
Fig 8: Caspase activation model in mitochondria  
Matrix swelling and channel opening are thw two main processes involving activation of 
mitochondria in response to triggers like ceramide, Bax etc. Based on the path followed 
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by mitochondria due to these triggers, either apoptosis or necrosis can occur (Adapted 
from Green & Reed, 1998). 
   Several factors like Ca2+ , Bax, ceramide and oxidants trigger mitochondria to 
release caspase activating proteins namely Cytochrome c and apoptosis-inducing factor 
(AIF). Two general mechanisms for release of caspase activating proteins are: matrix 
swelling and channel opening (Figure 8). In the case of matrix swelling, osmotic 
disequilibrium leads to rupture of the outer mitochondrial membrane, releasing cyto c and 
other such caspase activators in the cytosol.  Cells in which mitochondria has ruptured 
are prone to a nonapoptotic pathway of cell death, i.e. necrosis. The other mechanism 
involves channel opeining without rupture of membrane releasing cytochrome c and 
apaf-1 activating caspase-9, thus culminating into activation of caspase-3 and apoptosis 
(Green & Reed,1998). 
Apoptosis Pathways 
There are two main apoptosis pathways: extrinsic (death receptor mediated) and  
intrinsic (mitochondrial) (Figure 9). The extrinsic pathway is initiated by binding of 
ligands to the death receptors on cell surface. Death receptors are a part of the tumor 
necrosis factor (TNF) gene superfamily comprising of up to 20 proteins. The most well 
characterized ligands of these receptors to date are FasL, TNF-α, Apo3L, and Apo2L. 
Corresponding receptors are FasR, TNFR1, DR3, and DR4/DR5, respectively 
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(Ashkenazi, Holland, & Eckhardt, 2008). 
 
Fig 9: Pathways of Apoptosis (Adapted from Adams & Cory, 2007): Extrinsic pathway 
involves death receptors and activates caspase-8. Intrinsic pathway activates caspase-9. 
Caspase 8 and 9 both activate downstream effector caspase 3 which is mainly involved in 
apoptosis. 
 
The extrinsic pathway activates caspase-8 through FADD (Fas associated death 
domain protein). Binding of death receptors results in clustering of death receptor 
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domains and recruitment of adaptor molecules like FADD. FADD then activates caspase-
8 through formation of DISC (death initiation signaling complex). Oligomerization of 
caspase-8 upon DISC formation drives its activation through self cleavage.The intrinsic 
pathway, on the other hand activates caspase-9 in response to Apaf-1 (Apoptosis 
activating factor-1) and cytochrome c released from a damaged mitochondria.  The 
release of cytochrome c into the cytosol triggers caspase-3 activation through formation 
of the cytochrome c/Apaf-1/caspase-9-containing apoptosome complex. Once activated, 
caspase-9 or -8 activate downstream effector caspases i.e. caspases -3, 6 and 7 which 
bring about apoptosis and cell death (Fulda & Debatin, 2006; Kerr et al., 1972).  
 
NEUROINFLAMMATION 
Zimmer, Ennis, & Shipley (1997) studied sarin-induced seizures reaching the conclusion 
that these may also lead to neuroinflammation due to overstimulation of specific brain 
regions that can cause long-lasting impact on brain function. 
  Microglia are immune cells in the brain that function as phagocytes and help to 
eliminate debris from dying cells or apoptotic bodies. Altered neuronal function, 
ischemia, injury or infection are factors that contribute to rapid activation of microglia. 
Activated microglia migrate to site of insult (Smith, Das, Ray, & Banik, 2012). Microglia 
are responsible for release of pro-inflammatory cytokines like IL-1α, IL-1β and TNF-α, 
thus initiating the cytokine cascade (McGeer & McGeer, 1995). Once the cascade is 
initiated, astrocytes are activated and release their own inflammatory signals. 
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Uncontrolled inflammatory responses contribute to neuronal damage (Zimmer et al., 
1997). One of the more widely studied markers of inflammation is glial fibrillary acidic 
protein (GFAP). GFAP is a major constituent of intermediate filaments in astrocytes in 
the CNS. Intermediate filaments form networks that provide support and strength to cells. 
Several molecules of glial fibrillary acidic protein bind together to form the type of 
intermediate filament found in astroglial cells. Astroglial cells support and nourish cells 
in the brain and spinal cord. If brain or spinal cord cells are injured through trauma or 
disease, astroglial cells react by rapidly producing more glial fibrillary acidic protein 
(Middeldorp & Hol, 2011).Vijayan, Lee, & Eng (1990) concluded that neural trauma is 
responsible for an increase in GFAP correlating to astrocyte proliferation and 
hypertrophy. As a result, specific activity of GFAP can be helpful in understanding the 
onset of astrogliosis in neuronal damage. Astrocytes respond to all forms of CNS insults 
through the process of astrogliosis wherein there is an increase in the number of 
astrocytes. Astrogliosis changes the expression and morphology of astrocytes causing 
scar formation. Astrogliosis has been found to play a role in several diseases like hepatic 
encephalopathy, amyotropic lateral sclerosis etc. to name a few (Sofroniew & Vinters, 
2010). 
 
Current treatment for OP exposure  
Nerve agent intoxication treatment consists of decontamination, ventilation, 
administration of antidotes and supportive therapy. The three therapeutic drugs used for 
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nerve agent exposures are atropine, pralidoxime and diazepam (Nerve Agents, Medical 
Management of Chemical Casualties Handbook,1995). Atropine and Pralidoxime are 
available primarily as a combination named MARK-1 kit (Figure 10) for military 
use.Atropine is the primary antidote for nerve agent exposures. As a competitive 
antagonist of ACh at the muscarinic receptors, it limits the peripheral muscarinic 
symptoms. Atropine in packaged in an auto-injector in the MARK-1 kit with a dose of 2 
mg.  Oximes such as Pralidoxime (2-PAM) are used as antidotes in the MARK-1 kit. 
Available as a part of the combination with atropine in a dose of 600 mg, 2-PAM serves 
to break the nerve agent-enzyme bond thus restosing the activity ofAChE. The atropine 
and pralidoxime are packaged together as auto injectors and each military person gets 3 
MARK-1 kits.  There is also an additional auto-injector called convulsion antidote, nerve 
agent (CANA). CANA is supplied separately from MARK-1 kit and it includes diazepam 
as an anti-convulsant. Diazepam is used together with the MARK-1 combination to 
decrease convulsive activity and to reduce brain damage from prolonged seizure activity 
in a dose of 10 mg ( Rotenberg & Newmark, 2003; Wiener & Hoffman, 2004) 
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Fig 10:  A) Nerve Agent Antidote Kit (NAAK): MARK-1 includes atropine and 
pralidoxime as autoinjectors B) Additional convulsion antidote, nerve agent (CANA) is 
also provided with NAAK that consists of anti convulsant diazepam 
http://chemm.nlm.nih.gov/antidote_nerveagents.htm. 
 
Q-VD-OPh: Broad Spectrum Caspase Inhibitor 
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Caspases are effector molecules that play a key role in apoptosis. Caspase 
processing and activation is regulated by a number of molecules like FADD, Apaf-1 and 
Bcl-2 family. (Ekert, Silke, & Vaux, 1999). In response to a pro-apoptotic signal, initiator 
caspases, such as caspase 8, 9, 10 (plus a series of other proteins) are activated. These, in 
turn, cleave other effector caspases, which are the ones that effectively are responsible for 
apoptosis: caspase 3, 6, and 7 (Thornberry, 1998). Broad-spectrum caspase inhibitors 
permeate the cell membrane and alkylate the active site cysteine of caspases and 
irreversibly block apoptosis by preventing caspase activation, substrate cleavage, and 
DNA ladder formation. Z-VAD-FMK and related FMK (fluormethylketone) compounds 
are among the very first caspase inhibitors developed. However, the presence of FMK 
moeity that can produce highly toxic fluoroacetate moeity in vivo prevents the use of 
these compounds as therapeutic agents. Fluroacetate inhibits aconitase, an enzyme active 
in the citric acid cycle (series of chemical reactions to generate energy). Inhibition of 
aconitase damages mitochondria by leading to matrix swelling and loss of outer 
membrane of mitochondria (Van Noorden, 2001). 
Q-VD-OPh, a peptide-derived broad-spectrum caspase inhibitor irreversibly and 
effectively inhibits caspases. Improved potency, reduced cellular toxicity and stability are 
the major advantages with Q-VD-OPh in comparison to other caspase inhibitors such as 
z-VAD-FMK (Antar et al., 2009).  
 
FMK versus Q-VD-OPh as caspase inhibitors 
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Fluromethylketone (FMK) are specific caspase inhibitors developed according to 
the substrate cleavage sites in the caspases. They act as pseudosubstrates and hence are 
not competitive inhibitors. The inhibitors contain either a single aspartic acid group (eg. 
Boc-aspartyl(OMe)-fluoromethylketone: Boc-Asp-FMK), a trimer (eg. 
Benzyloxycarbonyl-val-ala-asp (OMe) fluoromethylketone: z-VAD-FMK) or a tetramer 
(eg. YVAD-FMK) (Ekert et al., 1999). Z-VAD-FMK and other FMKs became extremely 
popular as caspase inhibitors in basic and applied research in the 5 years since their 
development. However, FMKs will remain helpful only in scientific research and will 
never promote to become therapeutic targets due to the production of highly toxic 
fluoroacetate in vivo (Van Noorden, 2001). Boc-Asp-FMK and Z-VAD-FMK in higher 
doses may induce necrotic-like features attributable to production of fluoroacetate (Yang 
et al., 2004). When compared with Q-VD-OPh, the potency of Boc-D-FMK as an 
apoptosis inhibitor was found to be less or equal to Z-VAD-FMK. Q-VD-OPh decreased 
caspase-dependent apoptosis more significantly than did Z-VAD-FMK or Boc-D-FMK 
(Chauvier, Ankri, Charriaut-Marlangue, Casimir, & Jacotot, 2007). Improved potency, 
reduced cellular toxicity and stability are the major advantages with Q-VD-OPh in 
comparison to FMK caspase inhibitors (Antar et al., 2009). Furthermore, FMK is not as 
freely permeable to the blood brain barrier compared to Q-VD-OPh and Q-VE-OPh 
(Antar et al., 2009). 
Q-VE-OPh: Negative Control 
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Q-VE-OPh is a negative control for the broad spectrum caspase inhibitor Q-VD-
OPh. It includes the addition of a single carbon element to the aspartic acid residue 
changing it to glutamic acid  (Figure 11) Southerland et.al., 2010 found that Q-VE-OPh 
was 20 times less toxic than Q-VD-OPh.  
 
Fig 11: Structure of Q-VD-OPh and Q-VE-OPh 
Q-VD-OPh consists of aquinoline moeity that protects the two amino acids valine and 
aspartic acid from degradation and the OPh group that helps to eliminate in vivo toxicity. 
Q-VD-OPh and Q-VE-OPh were provided by Apoptrol, LLC. 
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Hypothesis and Specific Aims 
The large amount of evidence available to date indicates that the current treatment regime 
for OP exposure is ineffective in attenuating neurodegeneration and neuroinflammation 
outside the 40 minute window. The use of Q-VD-OPh as a broad spectrum caspase 
inhibitor which may be effective beyond 30-40 minutes of sarin exposure and can be 
made accessible to civilians as well lead to the development of the following hypothesis: 
Sarin-induced CNS neuroinflammation and neurodegeneration can be attenuated by the 
use of an in-vivo broad spectrum caspase inhibitor Q-VD-OPh. 
In order to study this hypothesis, we divided the outlined three specific aims. 
Specific Aim 1 
To establish the effect of CBDP, sarin, Q-VD-OPh and Q-VE-OPh on neuroinflammation 
and neurodegeneration in specific brain regions. 
Specific Aim 2 
To determine whether Q-VD-OPh can attenuate sarin-induced neuroinflammation. 
Specific Aim 3 
To test the hypothesis that Q-VD-OPh can attenuate sarin-induced neurodegeneration. 
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Materials and Methods 
In this study, adult female C57BL/6 mice were subjected to a dosing sequence 
simulating OP toxicity in humans via the injection of 1.5 mg/kg CBDP 
(cresylbenzodioxaphosphorin oxide) before a 0.04 mg/kg injection of sarin followed by 
20 mg/kg injection of Q-VD-OPh 30 minutes after sarin injections (Figure 12) 
Mechanistically, being able to stop or attenuate neuronal cell death after the 30-minute 
MARK-1 window, would constitute signifiacnt improvement on current treatment. 
 
Fig 12: Experimental Design: Mice were treated in a dosing sequence similar to human 
exposure starting with CBDP, followed by sarin, and finally followed by Q-VD-OPh or 
Q-VE-OPh 30 minutes after. 
The controls and sarin exposed mice were divided into six different groups. Table 
2 shows the groups in controls and sarin treated categories. For this study, the focus 
would mainly be on groups that received vehicles, vehicles+CBDP, CBDP+vehicle+Q-
VD-OPh and CBDP+vehicle+Q-VE-OPh for the control group. In case of sarin, study 
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will focus on groups that were treated with sarin, Q-VD-OPh with sarin and Q-VE-OPh 
with sarin. The numbers in paranthesis in table 2 indicate total number of animals per 
group, both the time points combined. 
Use of CBDP:  
Rodents, especially rats and mice express large amounts of carboxylestarse (CaE), 
an enzyme involved in the detoxification of OP agents. It is found predominantly in the 
lung, kidney, plasma and liver (Garrett, Rapp, Grubbs, Schlager, & Lucot, 2010). CaE 
irreversibly binds to sarin and thus reduces the amount of free sarin available to inhibit 
AChE. As a result higher doses of sarin are required per body weight in comparison to 
the dose that humans would need to produce toxicity (Maxwell, Brecht, & O’Neill, 
1987). Cresylbenzodioxaphosphorin oxide (CBDP),  a CaE inhibitor can be used to lower 
the dose of sarin required in the mice. By reducing the dose of sarin required to produce 
toxicity, CBDP reduces the complications of metabolites at higher levels than in humans 
(Casida & Quistad, 2004). At a dose of 1.5 mg/kg, CBDP does not inhibit AChE activity 
when used alone. However, when the mice are injected with CBDP prior to sarin 
injection, CBDP efficiently increases rodents’ susceptibility to OP poisoning, making 
their exposure at low doses more representative of human exposure (Bošković, 1978). 
In vivo sarin experiments were performed by MRI Global, Kansas City, MO. The brains 
were sent then sent to Wright State University and stored at -80°C until sectioned. 
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Table 2 – Treatment Groups for the Project 
TREATMENT GROUPS 
Control 
Glycol+Saline+DMSO (14) 
Glycol+Saline+Q-VE (14) 
Glycol+Saline+Q-VD (14) 
CBDP+Saline+DMSO (14) 
CBDP+Saline+Q-VE (11) 
CBDP+Saline+Q-VD (14) 
Sarin 
CBDP+Sarin (11) 
CBDP+Sarin+Q-VD (13) 
CBDP+Sarin+Q-VE (12) 
 
Table 3: Experimental Substances with dose and route of administration 
Name Concetration Vehicle Volume Route Frequency 
CBDP 1.5mg/kg 
Glycol & 
5% EtOH 
500µl SC 1 
Sarin 0.04mg/kg Saline 500µl SC 1 
Q-VD-OPh 20mg/kg DMSO 40µl IP 1 
Q-VE-OPh 20mg/kg DMSO 40µl IP 1 
 
CBDP (a generous gift of D.M. Maxwell) was diluted to 0.3 mg/ml in a 5% ethanol and 
propylene glycol solution for a dose of 1.5 mg/kg. Sarin (Aberdeen Proving Ground,MD) 
was diluted from a stock of 1.9 mg/ml in sterile saline and injected s.c. in a volume of 0.5 
ml/100 g. Q-VD-OPh and Q-VE-OPh were provided by Apoptrol, LLC. Q-VD-OPh and 
Q-VE-OPh were diluted in DMSO and 40 µl of each were injected intraperitoneally. 
Table 3 shows the concentraions of all the experimental substances used alongwith their 
route of administration. 
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Brain Sectioning and Tissue Collection 
At the 48-hour and 14-day time points, mice were sacrificed and brains were 
collected for histology. Brains were separated into left and right hemispheres. Brains 
were flash frozen in isopentane for 30 seconds and stored at -80°C until sectioned. The 
left half of the brain was used for sectioning and staining. The right half of the brain was 
used for cytokine analysis. Figure 13 shows the brain regions of interest for the study.  
Frozen brains to be used for staining were then thawed and mounted on a cryocassette, 
covered with tissue freezing medium and sliced on a cryotome (at approx. -20°C) 
throughout the brain regions inclusive of amygdala, hippocampus and piriform cortex at a 
thickness of 12μm. Sections were collected on slides and allowed to stay at room 
temperature overnight. Sections were then post-fixed by washing in a 4% 
paraformalaldehyde (PFA) solution for 10 minutes followed by washing in 1X PBS 
solution twice for 2 minutes and stored at -20°C. 
Brain regions of interest 
Brain regions most commonly affected by sarin exposure are amygdala, 
hippocampus and piriform cortex (Lemercier, Carpentier, Sentenac-Roumanou, & 
Morelis, 1983). Amygdala, piriform cortex and subfields of hippocampus namely dentate 
gyrus and CA2-CA3 show neuropathological lesions that can be linked to OP exposure 
(Spradling, Lumley, Robison, Meyerhoff, & Dillman, 2011). These brain regions are 
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associated with judgement, emotion, learning and memory (Dickerson & Eichenbaum, 
2010). 
Cytokine Analysis 
BioPlex Pro assays are immunoassays formatted on magnetic beads and work 
similar to sandwich ELISAs. Antibodies directed towards the desired biomarker are 
adhered to  beads. The antibody-bead  complex then reacts with the sample containing 
the biomarker of interest. The result of this technology is the potential to analyze up to 
100 different analytes in one volume of sample. Cytokine analysis was performed using 
the Bio-Plex 200 Pro Mouse Cytokine Grp I Panel (23-Plex) kit. For cytokine analysis 
using the BioPlex system, frozen brains were thawed and frontal cortex was collected in 
0.5 ml eppendorf tubes. The brain was then mounted on brain block having grooves that 
were 1 mm wide. Blades were inserted at 0 point (the point where brain stem attaches), 
between 1-3 and 3-4 in order to get three sections of 1 mm, 2 mm and 1 mm each from 
which discrete brain areas were hand dissected. Brain regions were selected using the 
landmarks in the handbook titled “The Mouse Brain in Stereotaxic Coordinates” to 
ensure that all the required regions were collected (Paxinos & Franklin, 2004). The 2 mm 
wide section was used to collect amygdala and hippocampus in 0.5 ml eppendorf tubes. 
The last 1 mm section was used to collect the piriform cortex. The sections were then 
stored at -80. For cytokine analysis, the sections were homogenized in 150 µl 1X PBS 
and protein concentration was determined using Bradford assay. Homogenized sections 
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were used for cytokine analysis using BioPlex (Bio Rad) Cytokine assay kit. In all, 11 
such kits were used to analyze cytokines in all mice brains listed in the groups in table 2, 
both amygdala and hippocampus in 2 day, 14 day The end result is a comprehensive 
panel of 23 cytokines for each animal.  
So far, most of the research has been focused on changes in IL-1α, IL-1β, TNF-α, 
IL-4 and IL-6 in response to sarin exposure. However, there are many more cytokines 
that are affected due to such organophosphate exposures. In this study, we have been able 
to analyze changes in 23 cytokines following sarin exposure. These 23 cytokines are a 
mix of pro and anti-inflammatory cytokines (Appendix table 15) 
Terminal deoxynucleotidyl transferase-mediated biotinylated UTP Nick End Labeling 
(TUNEL) Staining 
TUNEL staining was performed on brain sections using the NeuroTACS II In Situ 
Apoptosis Detection Kit. The slides were treated with Neuropore (50µl) for 30 minutes 
followed by 1X PBS wash twice for 2 minutes each. Hydrogen peroxide (6% ) was used 
as a quenching solution for 10 minutes to block endogenous peroxidase activity in brain 
and then slides were washed with 1X PBS four times for 3 minutes each. Sections were 
then treated with 1X TdT labeling buffer for 5 minutes before addition of labeling 
reaction mixture for 1 hour in a humidity chamber at 370C. To stop the reaction after an 
hour of incubation, the sections were treated with 1X TdT stop buffer for 5 minutes 
followed by 1X PBS washes. Two washes of 1% bovine albumin serum (BSA) and 
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0.05% tween in 1X PBS each for 2 minutes were done after a 10 minute incubation with 
the Strepavidin-HRP solution followed by 2 additional 1X PBS washes for 2 minutes. 
Sections were then dipped in DAB (diaminobenxidine) solution for 4 minutes and 
washed in ddH2O. Sections were counterstained with blue counterstain for 15 seconds 
and mounted using permount medium (Bricker, 2004; Davidson, 2007). 
Statistical Analysis 
Data was analyzed using STATISTICA (Statsoft, v12) software. Multivariate 
ANOVA was used to evaluate overall significance. A Fisher Least Significant Difference 
(LSD) post hoc test was used to evaluate individual group differences. P-values less than 
0.05 were considered to be significant. All values are reported as mean ± standard error.  
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Results 
CBDP, Q-VD-OPh, and Q-VE-OPh Had a Significant Effect on Cytokines in Specific 
Mouse Brain Regions. 
Two regions were excised from the brains and analyzed for cytokines (Figure 13). 
To manage the large amount of data available from the experiments, we will first analyze 
the controls, followed by the sarin-exposed with and without Q-VD-OPh. 
 
Figure 13: Coronal section of brain region containing the hippocampus CA2 and CA3 
(pink), amygdala (neon green), Dentate Gyrus (bright green), and piriform cortex 
(lavender). The line from top to bottom indicates where the brain was cut in two after 
removal from the skull.  
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To determine the effects of sarin and Q-VD-OPh on cytokines, it was first 
necessary to determine what effect the various vehicles and even CBDP had on them. 
First, glycerol and DMSO didn’t cause a significant change in cytokines at either 2 or 14 
days in either amygdala or hippocampus compared to saline alone (Appendix table 1). 
Table 4 shows the cytokine data from amygdala at day 2 comparing vehicle controls with 
CBDP. There was no significant difference in cytokines at this time point except for 
MIP-1α. At day 14, there appeared to be at least one cytokine, i.e., IL-17, that was 
decreased by 0.55 fold in response to CBDP, G-CSF also showed significant 
change(Table 5). When cytokines from the hippocampus were analyzed, the day 2 data 
showed a number of changes in response to CBDP. Specifically, IL-1α, IL-2, IL-6, and 
G-CSF were found to be significantly increased (Table 6). In contrast, IL-10, IL-12(p40), 
and IL-17 showed a significant decrease (Table 6). By day 14 post treatment, Rantes was  
the only cytokine to be significantly increased (Table 7).  
These results suggest that there was no change in most of the examined cytokines 
at either the 2 or 14 day time points in amygdala. In hippocampus, for many cytokines 
there was an initial increase in response to CBDP whereas some decreased at day 2 
(Figure 14). In general, there are up and down effects on cytokines at 2 day post CBDP 
treatment that are mostly resolved by day 14. 
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Fig 14: Diagram showing the effect of CBDP on cytokines at 2 and 14 day time points in 
amygdala and hippocampus. 
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Table 4: Effect of CBDP on Cytokines at 2 Days in Amygdala 
Cytokine Control (vehicles) 
Control (vehicles + 
CBDP) 
Change 
IL-1α 1.72 ± 0.22 1.48 ± 0.12 1.16 
IL-1β 56.59 ± 3.79 58.96 ± 1.40 1.04 
IL-2 8.00 ± 0.64 9.40 ± 0.34 1.17 
IL-3 0.72 ± 0.17 1.31 ± 0.08 1.80 
IL-4 OOR OOR - 
IL-5 3.24 ± 0.47 3.75 ± 0.22 1.15 
IL-6 0.90 ± 0.14 1.05 ± 0.09 1.16 
IL-9 127.35 ± 33.19 187.11 ± 12.81 1.46 
IL-10 10.56 ± 1.43 14.71 ± 0.72 1.00 
IL-12(p40) 9.34 ± 1.88 10.11 ± 0.61 1.08 
IL-12(p70) 24.34 ± 1.35 32.15 ± 1.77 1.32 
IL-13 96.20 ± 10.13 110.09 ± 3.78 1.14 
IL-17 19.75 ± 1.45 21.33 ± 1.32 1.08 
Eotaxin 99.24 ± 13.73 121.87 ± 9.47 1.22 
G-CSF OOR OOR - 
GM-CSF 28.29 ± 6.13 35.92 ± 2.76 1.26 
IFN-γ 9.55 ± 1.56 13.93 ± 1.22 1.45 
KC 4.39 ± 0.58 5.72 ± 0.26 1.30 
MCP-1 21.30 ± 3.48 26.79 ± 0.95 1.31 
MIP-1α 52.74 ± 27.86 OOR -  
MIP-1β  23.16 ± 4.16 18.38 ± 1.25 0.80 
Rantes 1.37 ± 0.42 3.81 ± 0.34 2.78 
TNF-α 225.90 ± 14.35 250.71 ± 6.97 1.10 
Table 4: Table showing the effect of CBDP on cytokines at 2 days in amygdala. The 
data represents protein concentration in pg/ml obtained by cytokine analysis. 
Significant data (p<0.05) is marked with *. Statistical significance was analyzed using 
2-way ANOVA followed by Fisher LSD post hoc test. Data are expressed as mean ± 
standard error. 
OOR: Out of range 
 
 
38 
 
 
 
 
 
 
 
 
Table 5: Effect of CBDP on Cytokines at 14 Days in Amygdala 
Cytokine Control (vehicles) 
Control (vehicles + 
CBDP) 
Change 
IL-1α 25.44 ± 25.19 30.43 ± 15.40 1.19 
IL-1β OOR OOR - 
IL-2 OOR < OOR < - 
IL-3 OOR < OOR < - 
IL-4 OOR < OOR < - 
IL-5 26.47 ± 24.84 11.83 ± 9.91 0.44 
IL-6 OOR < OOR < - 
IL-9 79.08 ± 21.92 67.32 ± 13.90 0.85 
IL-10 0.93 ± 0.08 31.10 ± 15.26 33.44 
IL-12(p40) OOR 100.01 ± 1.00 - 
IL-12(p70) OOR < OOR < - 
IL-13 29.51 ± 10.08 17.87 ± 3.06 0.60 
IL-17 189.72 ± 30.52 105.45 ± 4.86 0.55 * 
Eotaxin OOR < OOR < - 
G-CSF 75.86 ± 25.14 OOR - 
GM-CSF OOR < OOR < - 
IFN-γ 1.78 ± 0.18 2.54 ± 0.15 1.42 
KC OOR < OOR < - 
MCP-1 33.75 ± 22.72 18.61 ± 9.30 0.55 
MIP-1α OOR < OOR < - 
MIP-1β  2.08 ± 0.80 0.99 ± 0.22 0.47 
Rantes 0.44 ± 0.20 1.95 ± 0.34 4.43 
TNF-α 501.25 ± 55.11 481.26 ± 59.56 0.96 
Table 5: Table showing the effect of CBDP on cytokines at 14 days in amygdala. The 
data represents protein concentration in pg/ml obtained by cytokine analysis. 
Significant data (p<0.05) is marked with *. Statistical significance was analyzed using 
2-way ANOVA followed by Fisher LSD post hoc test. Data are expressed as mean ± 
standard error.OOR: Out of range 
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Table 6: Effect of CBDP on Cytokines at 2 Days in Hippocampus 
Cytokine Control (vehicles) 
Control (vehicles + 
CBDP) 
Change 
IL-1α 1.35 ± 0.23 60.79 ± 16.41 45.02 * 
IL-1β 20.53 ± 3.14 13.23 ± 1.72 0.64 
IL-2 1.41 ± 0.21 50.92 ± 16.69 36.11 * 
IL-3 OOR OOR - 
IL-4 0.48 ± 0.07 0.28 ± 0.03 0.58 
IL-5 1.37 ± 0.12 0.71 ± 0.12 0.52 
IL-6 0.38 ± 0.12 50.56 ± 16.81 133 * 
IL-9 46.40 ± 4.15 62.70 ± 12.90 1.35 
IL-10 3.94 ± 0.28 1.37 ± 0.34 0.34 * 
IL-12(p40) 2.58 ± 0.69 1.31 ± 0.17 0.50 * 
IL-12(p70) 8.50 ± 1.22 22.81 ± 13.04 2.68 
IL-13 25.69 ± 2.62 15.83 ± 2.35 0.61 
IL-17 5.78 ± 0.21 3.17 ± 0.49 0.54 * 
Eotaxin 79.68 ± 21.31 91.98 ± 9.01 1.15 
G-CSF 0.25 ± 0.09 50.57 ± 16.80 202.28 * 
GM-CSF 80.57 ± 20.43 83.66 ± 11.56 1.03 
IFN-γ 2.79 ± 0.15 2.14 ± 0.15 0.76 
KC 1.73 ± 0.15 1.25 ± 0.20 0.72 
MCP-1 7.00 ± 0.75 5.60 ± 1.67 0.8 
MIP-1α 3.71 ± 1.23 11.44 ± 9.96 3.08 
MIP-1β  9.43 ± 0.95 17.44 ± 3.00 1.84 
Rantes 0.71 ± 0.13 1.13 ± 0.30 1.59 
TNF-α 40.00 ± 2.94 24.80 ± 3.44 0.62 
Table 6 showing the effets of CBDP on cytokines at 2 days in hippocampus. The data        
represents protein concentration in pg/ml obtained by cytokine analysis. Significant 
data (p<0.05) is marked with *. Statistical significance was analyzed using 2-way 
ANOVA followed by Fisher LSD post hoc test. Data are expressed as mean ± standard 
error.  
OOR: Out of range 
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Sarin Elicits a Strong Cytokine Response in the Amygdala and Hippocampus  
The next question to be answered was whether cytokines would be affected by 
sarin as previous studies have indicated a response in a small number of cytokines. At the 
day 2 time point, in amygdala, there was a significant increase (p<0.05) seen in 13 
Table 7: Effect of CBDP on Cytokines at 14 Days in Hippocampus 
Cytokine Control (vehicles) 
Control (vehicles + 
CBDP) 
Change 
IL-1α 25.46 ± 25.18 21.04 ± 13.33 0.82 
IL-1β 13.32 ± 2.79 61.46 ± 20.53 4.61 
IL-2 0.55 ± 0.12 2.79 ± 0.97 5.07 
IL-3 OOR 71.72 ± 14.91 - 
IL-4 0.88 ± 0.02 1.65 ± 0.24 1.87 
IL-5 1.21 ± 0.17 1.79 ± 0.36 1.47 
IL-6 OOR 61.07 ± 16.30 - 
IL-9 OOR 90.07 ± 9.64 - 
IL-10 2.06 ± 0.95 7.15 ± 1.98 3.47 
IL-12(p40) 1.73 ± 0.68 4.05 ± 1.01 2.34 
IL-12(p70) 2.11 ± 1.02 12.15 ± 9.89 5.75 
IL-13 25.45 ± 5.26 72.17 ± 16.40 2.83 
IL-17 7.06 ± 1.34 7.47 ± 1.06 1.05 
Eotaxin OOR  393.21 ± 149.07 - 
G-CSF OOR 12.66 ± 9.87 - 
GM-CSF 52.61 ± 27.93 72.70 ± 14.41 1.38 
IFN-γ 1.27 ± 0.37 1.38 ± 0.35 1.08 
KC 1.07 ± 0.37 2.65 ± 0.51 2.47 
MCP-1 4.87 ± 1.18 13.26 ± 3.12 2.72 
MIP-1α OOR 71.14 ± 15.20 - 
MIP-1β  3.80 ± 0.88 7.36 ± 1.94 1.93 
Rantes 0.63 ± 0.27 2.07 ± 0.56 3.28 * 
TNF-α 28.08 ± 5.10 53.25 ± 11.26 1.89 
Table 7: Table showing the effect of CBDP on cytokines at 14 days in hippocampus. 
The data represents protein concentration in pg/ml obtained by cytokine analysis. 
Significant data (p<0.05) is marked with *. Statistical significance was analyzed using 
2-way ANOVA followed by Fisher LSD post hoc test. Data are expressed as mean ± 
standard error. 
OOR: Out of range 
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cytokine levels in comparison to control groups receiving CBDP alone (Table 8). In 
addition, there was a significant decrease (p<0.05) in three cytokines, IL-9, IFN-γ, and 
TNF-α.  
 At day 14, a significant decrease (p<0.05) was observed in IL-5, IL-10, IL-
12(p40), IL-17, G-CSF and TNF-α and a significant increase was observed in IL-13, 
IFN-γ and MIP-1β  in amygdala of sarin treated animals as compared to control animals 
(Table 9).  
In the hippocampus of sarin treated animals, an increase was seen in majority of the 
examined cytokines except IL-3, IL-12(p70), GM-CSF, MIP-1β and Rantes at the day 2 
time point (Table 10). By day 14 there appeared to be a change in a majority of the 
cytokines (Table 11). Similar to amygdala, hippocampus appeared to have a prolonged 
sarin effect. Of interest were the prolonged effects of sarin. Cytokines affected by sarin 
were found to change between 2 and 14 days (Table 12 and 13). Figure 15 summarizes 
the sarin induced changes in cytokines in both amygdala and hippocampus at both the 
time points. 
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Fig 15: Diagram showing the effect of sarin exposure on cytokines in amygdala and 
hippocampus at 2 and 14 day time point  
The next step was to check whether Q-VD-OPh had an effect on sarin induced 
changes in the cytokines. Following treatment with Q-VD-OPh, 8 out of the 13 cytokines 
that were increased post sarin treatment were found to be significantly decreased in 
amygdala at day 2 (Table14). However, Q-VD-OPh did not have an effect on any of the 
cytokines at day 14 in amygdala (Table 15).  
In case of hippocampus, none of the cytokines changed at day 2 (Table 16) whereas at 
day 14 only IFN-γ showed a significant decrease after treatment with Q-VD-OPh (Table 
17). Figure 16 summarizes the Q-VD-OPh effect on sarin induced cytokines at both time 
points in both the brain regions. 
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Fig 16: Diagram showing effect of Q-VD-OPh on sarin induced cytokines in amygdala 
nad hippocampus at 2 and 14 day time points. 
 
          The control Q-VE-OPh treated groups showed no significant change at the two or 
fourteen day time points in amygdala and hippocampus (Tables 18-21).  
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Table 8: Sarin Effect on Cytokines at 2 Days in Amygdala 
Cytokine Control (vehicles + CBDP) Sarin 
Change 
(Increase) 
IL-1α 1.48 ± 0.12 102.00 ± 0.00  68.9 * 
IL-1β 58.96 ± 1.40 169.42 ± 30.89  2.9 * 
IL-2 9.40 ± 0.34 10.08 ± 2.23  1.1 * 
IL-3 1.31 ± 0.08 4.50 ± 1.19 3.43 
IL-4 OOR 35.33 ± 33.33 - * 
IL-5 3.75 ± 0.22 6.27 ± 2.73 1.67 
IL-6 1.05 ± 0.09 4.14 ± 1.68 3.94 
IL-9 187.11 ± 12.81 102.00 ± 0.00  0.5 * 
IL-10 14.71 ± 0.72 21.50 ± 6.34  1.5 * 
IL-12(p40) 10.11 ± 0.61 7.09 ± 1.05 0.70 
IL-12(p70) 32.15 ± 1.77 101.66 ± 0.33  3.2 * 
IL-13 
110.09 ± 3.78 
394.55 ± 124. 
69  
3.6 * 
IL-17 21.33 ± 1.32 36.95 ± 18.62  1.7 * 
Eotaxin 121.87 ± 9.47 254.70 ± 63.11  2.1 * 
G-CSF OOR 3.92 ± 1.93 - 
GM-CSF 35.92 ± 2.76 61.38 ± 20.29  1.7 * 
IFN-γ 13.93 ± 1.22 2.36 ± 1.38  0.2 * 
KC 5.72 ± 0.26 10.98 ± 9.58  1.9 * 
MCP-1 26.79 ± 0.95 85.62 ± 31.30  3.2 * 
MIP-1α OOR  102.00 ± 0.57  - 
MIP-1β  18.38 ± 1.25 46.75 ± 5.76  2.5 * 
Rantes 3.81 ± 0.34 3.94 ± 1.78 1.03 
TNF-α 250.71 ± 6.97 123.38 ± 24.98  0.5 * 
Table 8: Table showing the effect of sarin on cytokines at 2 Days in Amygdala. The 
data represents protein concentration in pg/ml obtained by cytokine analysis. 
Significant data (p<0.05) is marked with *. Statistical significance was analyzed using 
2-way ANOVA followed by Fisher LSD post hoc test. Data are expressed as mean ± 
standard error. 
OOR: Out of range. 
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Table 9: Table showing the effect of sarin on cytokines at 14 Days in Amygdala. The 
data represents protein concentration in pg/ml obtained by cytokine analysis. Significant 
data (p<0.05) is marked with *. Statistical significance was analyzed using 2-way 
ANOVA followed by Fisher LSD post hoc test. Data are expressed as mean ± standard 
error. 
OOR: Out of range 
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Table 10: Effect of Sarin on Cytokines at 2 Days in Hippocampus 
Cytokine Control (vehicles + CBDP) Sarin Change 
IL-1α 60.79 ± 16.41 80.83 ± 20.16  1.32 * 
IL-1β 13.23 ± 1.72 107.39 ± 42.28  8.11 * 
IL-2 50.92 ± 16.69 6.96 ± 1.36  0.13 * 
IL-3 OOR 1.11 ± 0.29 - 
IL-4 0.28 ± 0.03 1.54 ± 0.30  5.5 * 
IL-5 0.71 ± 0.12 103.00 ± 0.71  145 * 
IL-6 50.56 ± 16.81 2.24 ± 0.66  0.04 * 
IL-9 62.70 ± 12.90 75.90 ± 20.22  1.21 * 
IL-10 1.37 ± 0.34 7.088 ± 1.93  5.17 * 
IL-12(p40) 1.31 ± 0.17 23.09 ± 19.49  17.62 * 
IL-12(p70) 22.81 ± 13.04 101.00 ± 0.00 4.42 
IL-13 15.83 ± 2.35 28.71 ± 6.66  1.81 * 
IL-17 3.17 ± 0.49 9.06 ± 1.37  2.85 *  
Eotaxin 91.98 ± 9.01 231.35 ± 83.88  2.51 * 
G-CSF 50.57 ± 16.80 83.75 ± 18.75  1.65 * 
GM-CSF 83.66 ± 11.56 84.31 ± 16.69 1.00 
IFN-γ 2.14 ± 0.15 24.00 ± 19.33  11.21 * 
KC 1.25 ± 0.20 68.07 ± 43.98  54.45 * 
MCP-1 5.60 ± 1.67 41.58 ± 29.53  7.42 * 
MIP-1α 11.44 ± 9.96 63.67 ± 23.06  5.56 * 
MIP-1β  17.44 ± 3.00 16.73 ± 6.30 0.95  
Rantes 1.13 ± 0.30 1.53 ± 0.36 1.35 
TNF-α 24.80 ± 3.44 133.37 ± 16.55  5.37 * 
Table 10: Table showing the effect of sarin on cytokines at 2 Days in Hippocampus. 
The data represents protein concentration in pg/ml obtained by cytokine analysis. 
Significant data (p<0.05) is marked with *. Statistical significance was analyzed using 
2-way ANOVA followed by Fisher LSD post hoc test. Data are expressed as mean ± 
standard error. 
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Table 11: Effect of Sarin on Cytokines at 14 Days in Hippocampus 
Cytokine Control (vehicles + CBDP) Sarin Change 
IL-1α 21.04 ± 13.33 OOR - 
IL-1β 61.46 ± 20.53 102.48 ± 14.00  1.66 * 
IL-2 2.79 ± 0.97 21.35 ± 5.00  7.65 * 
IL-3 71.72 ± 14.91 5.95 ± 0.64  0.08 * 
IL-4 1.65 ± 0.24 3.89 ± 0.35  2.35 * 
IL-5 1.79 ± 0.36 3.77 ± 0.45  2.10 * 
IL-6 61.07 ± 16.30 4.28 ± 0.62  0.07 * 
IL-9 90.07 ± 9.64 OOR - 
IL-10 7.15 ± 1.98 17.21 ± 1.82 2.40 
IL-12(p40) 4.05 ± 1.01 12.83 ± 0.53  3.16 * 
IL-12(p70) 12.15 ± 9.89 18.25 ± 3.34 1.50 
IL-13 72.17 ± 16.40 167.84 ± 21.43  2.32 * 
IL-17 7.47 ± 1.06 32.97 ± 2.75  4.41 * 
Eotaxin 393.21 ± 149.07 243.44 ± 51.31 0.61 
G-CSF 12.66 ± 9.87 2.75 ± 0.42  0.21 * 
GM-CSF 72.70 ± 14.41 45.17 ± 8.68  0.62 * 
IFN-γ 1.38 ± 0.35 9.12 ± 0.93 6.60 * 
KC 2.65 ± 0.51 7.78 ± 0.72  2.93 * 
MCP-1 13.26 ± 3.12 35.94 ± 3.61 2.71 
MIP-1α 71.14 ± 15.20 7.43 ± 1.56 0.10 * 
MIP-1β  7.36 ± 1.94 86.94 ± 31.45 11.81 * 
Rantes 2.07 ± 0.56 5.80 ± 0.63 2.80 
TNF-α 53.25 ± 11.26 248.2 ± 53.3 4.66 * 
Table 11: Table showing the effect of sarin on cytokines at 14 Days in Hippocampus. 
The data represents protein concentration in pg/ml obtained by cytokine analysis. 
Significant data (p<0.05) is marked with *. Statistical significance was analyzed using 
2-way ANOVA followed by Fisher LSD post hoc test. Data are expressed as mean ± 
standard error. 
OOR: Out of range 
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Table 12: Sarin effect at 2 days and 14 days in Amygdala 
Cytokine 2 Days 14 days Change 
IL-1α 102.00 ± 0.00  67.55 ± 21.15 0.66 
IL-1β 169.42 ± 30.89  90.37 ± 30.26 0.53 
IL-2 10.08 ± 2.23  10.05 ± 3.32 0.99 
IL-3 4.50 ± 1.19 34.27 ± 21.02 7.61 
IL-4 35.33 ± 33.33 3.16 ± 1.11 11.18 
IL-5 6.27 ± 2.73 3.66 ± 1.41  0.58 
IL-6 4.14 ± 1.68 2.90 ±  0.92 0.70 
IL-9 OOR OOR < -  
IL-10 21.50 ± 6.34  14.79 ± 5.43  0.68 
IL-12(p40) 7.09 ± 1.05 5.73 ± 1.69  0.80 
IL-12(p70) 101.66 ± 0.33  84.19 ± 16.81 0.82 
IL-13 394.55 ± 124. 69  275.19 ± 99.22  0.69 
IL-17 36.95 ± 18.62  31.88 ± 10.51  0.86 
Eotaxin 254.70 ± 63.11  87.14 ± 13.13 0.34 * 
G-CSF 3.92 ± 1.93 3.77 ± 1.38  0.96 
GM-CSF 61.38 ± 20.29  45.37 ± 17.79 0.73 
IFN-γ 2.36 ± 1.38  51.36 ± 22.21  21.76 
KC 10.98 ± 9.58  2.37 ± 0.63 0.21 
MCP-1 85.62 ± 31.30  47.58 ± 17.31 0.55 
MIP-1α 102.00 ± 0.57  84.42 ± 16.58 0.82 * 
MIP-1β  46.75 ± 5.76  32.47 ± 7.97  0.69 
Rantes 3.94 ± 1.78 2.00 ± 0.67  0.50 
TNF-α 123.38 ± 24.98  127.55 ± 30.00  1.03 
Table 12: Table showing the effect of sarin at 2 days and 14 days in Amygdala. The 
data represents protein concentration in pg/ml obtained by cytokine analysis. 
Significant data (p<0.05) is marked with *. Statistical significance was analyzed using 
2-way ANOVA followed by Fisher LSD post hoc test. Data are expressed as mean ± 
standard error. 
OOR: Out of range. 
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Table 13: Sarin effect at 2 days and 14 days in Hippocampus 
Cytokine 48 hours 14 days Change 
IL-1α 80.83 ± 20.16  OOR - 
IL-1β 107.39 ± 42.28  102.48 ± 14.00  0.95 
IL-2 6.96 ± 1.36  21.35 ± 5.00  3.06* 
IL-3 1.11 ± 0.29 5.95 ± 0.64  5.36* 
IL-4 1.54 ± 0.30  3.89 ± 0.35  2.52* 
IL-5 103.00 ± 0.71  3.77 ± 0.45  0.03* 
IL-6 2.24 ± 0.66  4.28 ± 0.62  1.91 
IL-9 75.90 ± 20.22  OOR - 
IL-10 7.088 ± 1.93  17.21 ± 1.82 2.43* 
IL-12(p40) 23.09 ± 19.49  12.83 ± 0.53  0.55* 
IL-12(p70) OOR 18.25 ± 3.34  - 
IL-13 28.71 ± 6.66  167.84 ± 21.43  5.84* 
IL-17 9.06 ± 1.37  32.97 ± 2.75  3.63* 
Eotaxin 231.35 ± 83.88  243.44 ± 51.31 1.05 
G-CSF 83.75 ± 18.75  2.75 ± 0.42  0.03 
GM-CSF 84.31 ± 16.69 45.17 ± 8.68  0.53 
IFN-γ 24.00 ± 19.33  9.12 ± 0.93 0.38* 
KC 68.07 ± 43.98  7.78 ± 0.72  0.11 
MCP-1 41.58 ± 29.53  35.94 ± 3.61 0.86 
MIP-1α 63.67 ± 23.06  7.43 ± 1.56 0.11 
MIP-1β  16.73 ± 6.30 86.94 ± 31.45 5.19 
Rantes 1.53 ± 0.36 5.80 ± 0.63 3.79* 
TNF-α 133.37 ± 16.55  248.2 ± 53.3 1.86 
Table 13: Table showing the effect of sarin at 2 days and 14 days in hippocampus. The 
data represents protein concentration in pg/ml obtained by cytokine analysis. 
Significant data (p<0.05) is marked with *. Statistical significance was analyzed using 
2-way ANOVA followed by Fisher LSD post hoc test. Data are expressed as mean ± 
standard error. OOR: Out of range. 
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Table 14: Effect of Q-VD-OPh on Sarin-Induced Cytokines at 2 Days in 
Amygdala 
Cytokine Sarin Sarin+Q-VD-OPh Change 
IL-1α OOR OOR - 
IL-1β 169.42 ± 30.89 97.76 ± 15.11  0.57 * 
IL-2 10.08 ± 2.23 7.23 ± 0.69  0.71 * 
IL-3 4.50 ± 1.19 2.04 ± 0.43  0.45 * 
IL-4 OOR OOR - 
IL-5 6.27 ± 2.73 2.30 ± 0.90 0.36 
IL-6 4.14 ± 1.68 2.28 ± 0.44 0.55 
IL-9 OOR OOR - 
IL-10 21.50 ± 6.34 12.21 ± 2.18  0.56 * 
IL-12(p40) 7.09 ± 1.05 3.99 ± 0.77  0.56 * 
IL-12(p70) 101.66 ± 0.33 103.00 ± 0.52 1.01 
IL-13 394.55 ± 124. 69 210.94 ± 45.97  0.53 * 
IL-17 36.95 ± 18.62 18.60 ± 5.35 0.50 
Eotaxin 254.70 ± 63.11 219.06 ± 33.46 0.86 
G-CSF 3.92 ± 1.93 1.93 ± 0.53 0.49 
GM-CSF 61.38 ± 20.29 53.58 ± 11.63 0.87 
IFN-γ 2.36 ± 1.38 18.00 ± 16.60 7.62 
KC 10.98 ± 9.58 1.34 ± 0.20 0.12 
MCP-1 85.62 ± 31.30 44.70 ± 9.92 0.52 
MIP-1α 102.00 ± 0.57 88.71 ± 16.90 0.86 
MIP-1β  46.75 ± 5.76 26.62 ± 4.83  0.56 * 
Rantes 3.94 ± 1.78 1.48 ± 0.43 0.37 
TNF-α 123.38 ± 24.98 72.26 ± 11.95  0.58 * 
Table 14: Table showing the effect of Q-VD-OPh on Sarin-Induced Cytokines at 2 
Days in Amygdala. The data represents protein concentration in pg/ml obtained by 
cytokine analysis. Significant data (p<0.05) is marked with *. Statistical significance 
was analyzed using 2-way ANOVA followed by Fisher LSD post hoc test. Data are 
expressed as mean ± standard error. OOR: Out of range 
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Table 15: Effect of Q-VD-OPh on Cytokines at 14 Days in Amygdala 
Cytokine Sarin Sarin+Q-VD-OPh Change 
IL-1α 67.55 ± 21.15 OOR - 
IL-1β 90.37 ± 30.26 88.75 ± 24.58 0.98 
IL-2 10.05 ± 3.32 9.88 ± 2.70 0.98 
IL-3 34.27 ± 21.02 21.58 ± 19.87 0.62 
IL-4 3.16 ± 1.11 3.19 ± 1.06 1.00 
IL-5 3.66 ± 1.41 3.95 ± 1.75 1.07 
IL-6 2.90 ±  0.92 3.24 ± 0.99 1.11 
IL-9 OOR < OOR < - 
IL-10 14.79 ± 5.43 14.38 ± 5.13 0.97 
IL-12(p40) 5.73 ± 1.69 6.07 ± 1.45 1.05 
IL-12(p70) 84.19 ± 16.81 44.34 ± 23.31 0.52 
IL-13 275.19 ± 99.22 276.15 ± 101.89 1.00 
IL-17 31.88 ± 10.51 30.62 ± 9.60 0.96 
Eotaxin 87.14 ± 13.13 82.39 ± 22.62 0.94 
G-CSF 3.77 ± 1.38 3.99 ± 2.04 1.05 
GM-CSF 45.37 ± 17.79 41.59 ± 16.59 0.91 
IFN-γ 51.36 ± 22.21 42.23 ± 24.01 0.82 
KC 2.37 ± 0.63 2.61 ± 0.79 1.10 
MCP-1 47.58 ± 17.31 47.51 ± 21.49 0.99 
MIP-1α 84.42 ± 16.58 60.94 ± 24.53 0.72 
MIP-1β  32.47 ± 7.97 42.58 ± 8.47 1.31 
Rantes 2.00 ± 0.67 2.44 ± 0.76 1.22 
TNF-α 127.55 ± 30.00 151.55 ± 48.58 1.18 
Table 15: Table showing the effect of Q-VD-OPh on Sarin-Induced Cytokines at 14 
Days in Amygdala. The data represents protein concentration in pg/ml obtained by 
cytokine analysis. Significant data (p<0.05) is marked with *. Statistical significance 
was analyzed using 2-way ANOVA followed by Fisher LSD post hoc test. Data are 
expressed as mean ± standard error. 
OOR: Out of range. 
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Table 16: Effect of Q-VD-OPh on Cytokines at 2 Days in Hippocampus 
Cytokine Sarin Sarin/Q-VD-OPh Change 
IL-1α 80.83 ± 20.16 OOR - 
IL-1β 107.39 ± 42.28 107.08 ± 15.12 0.99 
IL-2 6.96 ± 1.36 7.84 ± 0.69 1.12 
IL-3 1.11 ± 0.29 1.12 ± 0.14 1.00 
IL-4 1.54 ± 0.30 1.74 ± 0.15 1.12 
IL-5 103.00 ± 0.71 108.50 ± 0.76 1.05 
IL-6 2.24 ± 0.66 2.15 ± 0.18 0.95 
IL-9 75.90 ± 20.22 63.36 ± 5.97 0.83 
IL-10 7.088 ± 1.93 6.81 ± 0.43 0.96 
IL-12(p40) 23.09 ± 19.49 20.54 ± 16.30 0.88 
IL-12(p70) 101.00 ± 0.00 84.72 ± 16.28 0.83 
IL-13 28.71 ± 6.66 48.23 ± 9.62 1.67 
IL-17 9.06 ± 1.37 15.54 ± 2.29 1.71 
Eotaxin 231.35 ± 83.88 184.50 ± 36.93 0.79 
G-CSF 83.75 ± 18.75 97.82 ± 9.19 1.16 
GM-CSF 84.31 ± 16.69 75.59 ± 16.07 0.89 
IFN-γ 24.00 ± 19.33 37.26 ± 20.63 1.55 
KC 68.07 ± 43.98 29.92 ± 15.60 0.43 
MCP-1 41.58 ± 29.53 22.73 ± 10.08 0.54 
MIP-1α 63.67 ± 23.06 89.10 ± 12.90 1.39 
MIP-1β  16.73 ± 6.30 15.94 ± 2.14 0.95 
Rantes 1.53 ± 0.36 2.40 ± 0.80 1.56 
TNF-α 133.37 ± 16.55 148.92 ± 14.84 1.11 
Table 16: Table showing the effect of Q-VD-OPh on Sarin-Induced Cytokines at 2 
Days in hippocampus. The data represents protein concentration in pg/ml obtained by 
cytokine analysis. Significant data (p<0.05) is marked with *. Statistical significance 
was analyzed using 2-way ANOVA followed by Fisher LSD post hoc test. Data are 
expressed as mean ± standard error. 
OOR: Out of range 
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Table 17: Effect of Q-VD-OPh on Cytokines at 14 Days in Hippocampus 
Cytokine Sarin Sarin/Q-VD-OPh Change 
IL-1α OOR 80.85 ± 20.15 - 
IL-1β 102.48 ± 14.00 62.09 ± 9.43 0.60 
IL-2 21.35 ± 5.00 11.70 ± 1.77 0.54 
IL-3 5.95 ± 0.64 3.98 ± 0.53 0.67 
IL-4 3.89 ± 0.35 2.95 ± 0.33 0.75 
IL-5 3.77 ± 0.45 2.72 ± 0.25 0.72 
IL-6 4.28 ± 0.62 2.83 ± 0.40 0.66 
IL-9 OOR OOR - 
IL-10 17.21 ± 1.82 13.94 ± 2.27 0.80 
IL-12(p40) 12.83 ± 0.53 12.27 ± 1.22 0.95 
IL-12(p70) 18.25 ± 3.34 31.30 ± 17.48 1.71 
IL-13 167.84 ± 21.43 147.35 ± 21.32 0.87 
IL-17 32.97 ± 2.75 32.94 ± 2.78 0.99 
Eotaxin 243.44 ± 51.31 278.04 ± 64.65 1.14 
G-CSF 2.75 ± 0.42 1.86 ± 0.22 0.67 
GM-CSF 45.17 ± 8.68 28.58 ± 3.01 0.63 
IFN-γ 9.12 ± 0.93 5.87 ± 1.11  0.64 * 
KC 7.78 ± 0.72 6.09 ± 0.33 0.78 
MCP-1 35.94 ± 3.61 28.97 ± 2.42 0.80 
MIP-1α 7.43 ± 1.56 4.67 ± 0.93 0.62 
MIP-1β  86.94 ± 31.45 25.25 ± 11.71 0.29 
Rantes 5.80 ± 0.63 3.66 ± 0.28 0.63 
TNF-α 248.2 ± 53.3 224.0 ± 62.5 0.90 
Table 17: Table showing the effect of Q-VD-OPh on Sarin-Induced Cytokines at 14 
Days in hippocampus. The data represents protein concentration in pg/ml obtained by 
cytokine analysis. Significant data (p<0.05) is marked with *. Statistical significance 
was analyzed using 2-way ANOVA followed by Fisher LSD post hoc test. Data are 
expressed as mean ± standard error. 
OOR: Out of range 
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Table 18: Effect of Q-VE-OPh on Cytokines at 2 Days in Amygdala 
Cytokine Sarin Q-VE-OPh Change 
IL-1α OOR     OOR - 
IL-1β 169.42 ± 30.89 139.93 ± 12.86 0.82 
IL-2 10.08 ± 2.23 8.82 ± 0.51 0.87 
IL-3 4.50 ± 1.19 3.85 ± 0.73 0.85 
IL-4 OOR OOR - 
IL-5 6.27 ± 2.73 6.17 ± 1.47 0.98 
IL-6 4.14 ± 1.68 3.83 ± 0.52 0.92 
IL-9 OOR OOR - 
IL-10 21.50 ± 6.34 19.30 ± 2.60 0.89 
IL-12(p40) 7.09 ± 1.05 5.88 ± 0.83 0.82 
IL-12(p70) 101.66 ± 0.33 103.80 ± 1.11 1.02 
IL-13 394.55 ± 124. 69 360.31 ± 53.08 0.91 
IL-17 36.95 ± 18.62 32.94 ± 5.99 0.89 
Eotaxin 254.70 ± 63.11 223.76 ± 27.15 0.87 
G-CSF 3.92 ± 1.93 5.61 ± 1.42 1.43 
GM-CSF 61.38 ± 20.29 58.64 ± 5.95 0.95 
IFN-γ 2.36 ± 1.38 2.18 ± 0.49 0.92 
KC 10.98 ± 9.58 6.29 ± 3.94 0.57 
MCP-1 85.62 ± 31.30 86.19 ± 17.59 1.00 
MIP-1α 102.00 ± 0.57 107.00 ± 0.63 1.04 
MIP-1β  46.75 ± 5.76 36.82 ± 3.38 0.78 
Rantes 3.94 ± 1.78 3.28 ± 0.78 0.83 
TNF-α 123.38 ± 24.98 98.80 ± 5.69 0.80 
Table 18: Table showing the effect of Q-VE-OPh on Cytokines at 2 Days in 
Amygdala. The data represents protein concentration in pg/ml obtained by cytokine 
analysis. Significant data (p<0.05) is marked with *. Statistical significance was 
analyzed using 2-way ANOVA followed by Fisher LSD post hoc test. Data are 
expressed as mean ± standard error. 
OOR: Out of range 
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Table 19: Effect of Q-VE-OPh on Cytokines at 2 Days in Hippocampus 
Cytokine Sarin Q-VE-OPh Change 
IL-1α 80.83 ± 20.16 OOR - 
IL-1β 107.39 ± 42.28 106.46 ± 16.80 0.99 
IL-2 6.96 ± 1.36 7.66 ± 1.12 1.10 
IL-3 1.11 ± 0.29 1.13 ± 0.15 1.01 
IL-4 1.54 ± 0.30 1.66 ± 0.19 1.07 
IL-5 103.00 ± 0.71 114.50 ± 0.76  1.11 * 
IL-6 2.24 ± 0.66 19.26 ± 16.35 8.59 
IL-9 75.90 ± 20.22 70.26 ± 11.00 0.92 
IL-10 7.088 ± 1.93 6.51 ± 1.01 0.91 
IL-12(p40) 23.09 ± 19.49 3.79 ± 0.41 0.16 
IL-12(p70) OOR OOR - 
IL-13 28.71 ± 6.66 46.01 ± 10.71 1.60 
IL-17 9.06 ± 1.37 14.66 ± 4.35 1.61 
Eotaxin 231.35 ± 83.88 119.47 ± 40.86 0.51 
G-CSF 83.75 ± 18.75 68.02 ± 19.40 0.81 
GM-CSF 84.31 ± 16.69 88.59 ± 12.41 1.05 
IFN-γ 24.00 ± 19.33 21.01 ± 16.61 0.87 
KC 68.07 ± 43.98 43.61 ± 30.43 0.64 
MCP-1 41.58 ± 29.53 64.27 ± 25.51 1.54 
MIP-1α 63.67 ± 23.06 58.01 ± 20.64 0.91 
MIP-1β  16.73 ± 6.30 18.83 ± 4.73 1.12 
Rantes 1.53 ± 0.36 4.81 ± 1.85 3.14 
TNF-α 133.37 ± 16.55 124.11 ± 10.02 0.93 
Table 19: Table showing the effect of Q-VE-OPh on Cytokines at 2 Days in 
hippocampus. The data represents protein concentration in pg/ml obtained by cytokine 
analysis. Significant data (p<0.05) is marked with *. Statistical significance was 
analyzed using 2-way ANOVA followed by Fisher LSD post hoc test. Data are 
expressed as mean ± standard error. OOR: Out of range 
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Table 20: Effect of Q-VE-OPh on Cytokines at 14 Days in Amygdala 
Cytokine Sarin Q-VE-OPh Change 
IL-1α 67.55 ± 21.15 67.37 ± 12.70 0.99 
IL-1β 90.37 ± 30.26 69.47 ± 12.64 0.76 
IL-2 10.05 ± 3.32 6.89 ± 0.69 0.68 
IL-3 34.27 ± 21.02 35.13 ± 20.83 1.02 
IL-4 3.16 ± 1.11 2.35 ± 0.39 0.74 
IL-5 3.66 ± 1.41 3.39 ± 0.78 0.92 
IL-6 2.90 ±  0.92 2.63 ± 0.48 0.90 
IL-9 OOR < OOR < - 
IL-10 14.79 ± 5.43 14.46 ± 2.15 0.97 
IL-12(p40) 5.73 ± 1.69 4.86 ± 0.73 0.84 
IL-12(p70) 84.19 ± 16.81 51.10 ± 22.32 0.60 
IL-13 275.19 ± 99.22 249.19 ± 57.44 0.90 
IL-17 31.88 ± 10.51 29.24 ± 4.47 0.91 
Eotaxin 87.14 ± 13.13 75.09 ± 13.76 0.86 
G-CSF 3.77 ± 1.38 3.47 ± 1.02 0.92 
GM-CSF 45.37 ± 17.79 48.55 ± 17.13 1.07 
IFN-γ 51.36 ± 22.21 18.01 ± 16.60 0.35 
KC 2.37 ± 0.63 2.34 ± 0.39 0.98 
MCP-1 47.58 ± 17.31 43.89 ± 11.36 0.92 
MIP-1α 84.42 ± 16.58 84.23 ± 16.76 0.99 
MIP-1β  32.47 ± 7.97 20.73 ± 1.26 0.63 
Rantes 2.00 ± 0.67 2.13 ± 0.31 1.06 
TNF-α 127.55 ± 30.00 93.26 ± 10.67 0.73 
Table 20: Table showing the effect of Q-VE-OPh on Cytokines at 14 Days in 
Amygdala. The data represents protein concentration in pg/ml obtained by cytokine 
analysis. Significant data (p<0.05) is marked with *. Statistical significance was 
analyzed using 2-way ANOVA followed by Fisher LSD post hoc test. Data are 
expressed as mean ± standard error. OOR: Out of range 
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Table 21: Effect of Q-VE-OPh on Cytokines at 14 Days in Hippocampus 
Cytokine Sarin Q-VE-OPh Change 
IL-1α OOR OOR - 
IL-1β 102.48 ± 14.00 95.95 ± 19.62 0.93 
IL-2 21.35 ± 5.00 23.37 ± 1.94 1.09 
IL-3 5.95 ± 0.64 3.55 ± 0.53  0.59 * 
IL-4 3.89 ± 0.35 3.68 ± 0.46 0.94 
IL-5 3.77 ± 0.45 3.48 ± 0.45 0.92 
IL-6 4.28 ± 0.62 4.27 ± 0.65 0.99 
IL-9 OOR OOR - 
IL-10 17.21 ± 1.82 15.74 ± 2.13 0.91 
IL-12(p40) 12.83 ± 0.53 10.15 ± 0.31 0.79 
IL-12(p70) 18.25 ± 3.34  25.55 ± 15.22  1.4 
IL-13 167.84 ± 21.43 176.51 ± 20.46 1.05 
IL-17 32.97 ± 2.75 35.49 ± 3.23 1.07 
Eotaxin 243.44 ± 51.31 160.95 ± 21.87 0.66 
G-CSF 2.75 ± 0.42 2.86 ± 0.36 1.04 
GM-CSF 45.17 ± 8.68 36.67 ± 5.53 0.81 
IFN-γ 9.12 ± 0.93 6.72 ± 0.33 0.73 
KC 7.78 ± 0.72 7.28 ± 0.36 0.93 
MCP-1 35.94 ± 3.61 35.77 ± 3.13 1.00 
MIP-1α 7.43 ± 1.56 5.16 ± 0.88 0.69 
MIP-1β  86.94 ± 31.45 76.01 ± 26.44 0.87 
Rantes 5.80 ± 0.63 3.65 ± 0.20 0.62 
TNF-α 248.2 ± 53.3 273.5 ± 29.9 1.10 
Table 21: Table showing the effect of Q-VE-OPh on Cytokines at 14 Days in 
hippocampus. The data represents protein concentration in pg/ml obtained by cytokine 
analysis. Significant data (p<0.05) is marked with *. Statistical significance was 
analyzed using 2-way ANOVA followed by Fisher LSD post hoc test. Data are 
expressed as mean ± standard error. 
OOR: Out of range. 
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NEURODEGENERATION 
TUNEL Staining 
Apoptosis causes DNA strand breaks at ~180 bps that can be observed by agarose 
gel electrophoresis. The TUNEL assay is used to detect cell death from apoptosis by 
labeling these enzymatically degraded DNA fragments with polymerase terminal 
deoxynucleotide transferase (TdT) at the 3’-OH end. In our study, at 2 days there were no  
TUNEL positive cells in the sections that were not treated with sarin. However, Sarin-
treated sections showed an increase in the TUNEL positive staining as compared to the 
controls. Furthermore, TUNEL staining was seen to be less strong in brain sections from 
Q-VD-OPh treated animals. When Q-VE-OPh-sections were compared to sarin treated 
sections, there did not seem to be much difference in positive staining. However, when 
compared to Q-VD-OPh treated sections, Q-VE-OPh showed more intense staining than 
Q-VD-OPh (Fig 17). At the 14-day time point, there was no significant difference 
observed in TUNEL positive staining in sarin-treated brain sections compared to Q-VD-
OPh treated sections or Q-VE-OPh treated sections (Fig 18). Also, there did not seem to 
be much difference in TUNEL positive staining in sarin treated brain sections at 2 and 14 
day time points. But an increase in positive staining was observed in sarin treated 
sections in comparison to CBDP treated sections at 14 days.  
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Fig 17: TUNEL staining on dentate gyrus region of brain at day 2 
 No positive staining was observed in brain sections treated with Vehicles + CBDP (a), 
Increased positive TUNEL staining observed in brain sections treated with CBDP + Sarin 
(b), Positive staining was seen to be decreased in sections treated with CBDP+Sarin+Q-
VD-OPh (c), Not much difference observed in positive staining in sections treated with 
Q-VE-OPh compared to sarin treated sections but the difference is observable in 
comparison to sections treated with Q-VD-OPh (d) 
 
 
a b 
c d 
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Fig 18: TUNEL staining on dentate gyrus region of brain at 14 days  
There is very minute difference observed in TUNEL positive staining in sections treated 
with Vehicles + CBDP (a) and those treated with sarin (b). Not much difference is 
observed in TUNEL positive staining in brain sections treated with CBDP + Sarin (b) or 
those treated with CBDP+Sarin+Q-VD-OPh (c)  and Q-VE-OPh (d) treated sections.  
 
APOPTOTIC MARKER ANALYSIS 
a b 
c d 
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To further examine the potential for Q-VD-OPh to inhibit neurodegeneration, we 
analyzed several well-established markers of apoptosis using a BioPlex kit for Apoptosis. 
The kit we used examined 4 sets of apoptotic markers: Caspase 3, an effector in the 
caspase pathway; BCL-xL Bak Dimer and MCL-1 Bak Dimer and Survivin, an inhibitor 
of apoptosis. BCL is a family of proteins involved in the apoptosis pathway. Cell death is 
found to be regulated by BCL proteins. MCL dimer belongs to BCL family as well 
(Adams & Cory, 2007). Hence, BCL and MCL are both important markers of apoptosis. 
Due to the use of brain tissue for the other studies, we were only able to use frontal cortex 
tissue for this part of the project.  
Results show that caspase 3 was activated in a majority of the samples at 2 and 14 
days with 2-day levels being nearly double those at 14 days. Q-VD-OPh was not able to 
attenuate active caspase 3 levels at these time points. Q-VE-OPh as expected appeared to 
have no effect on activated caspase 3 levels. Next the levels of two markers of cell 
protection, i.e., BCL-xL BakDimer and Mcl-1 BakDimer, were analyzed. BCL-xL 
BakDimer was found to be 75% higher at 2 days than at 14 days. Q-VD-OPh did not 
appear to have an effect at 14 days, but showed a trend at 2 days. Mcl-1 Bak Dimer was 
found to be nearly the same at both 2 and 14 days.  Q-VD-OPh did not appear to have a 
significant effect at either time point. Q-VE-OPh did appear to trend lower at 2 days 
compared to 14 days. Finally, we analyzed Survivin, another protective marker which 
was below the detectable limit in most of the samples and thus we were not able to 
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determine if there was a change or not. At both time points survivin levels were too low 
to make a determination (Appendix Table 13 and 14). 
 
CHOLINESTERASE ANALYSIS 
 In this project we have studied what happens to cytokines and apoptotic markers 
in experiments with sarin and caspase inhibitors. The final analysis was to determine if 
Q-VD-OPh had an effect on acetylcholinesterase in brain tissue (Frontal Cortex). The 
results showed that Q-VD-OPh did not  have an inhibitory effect in mice treated with it 
and sarin (Fig 17). Q-VE-OPh also did not have a significant effect on sarin inhibition of 
acetylcholinesterase.  
Because of use of tissues for other experiments, we could only use frontal cortex from 
day 2 for this analysis. Also, we could only analyze sarin treated animals for AChE 
activity. The number of animals in each group is as follows: CBDP+Sarin – 4; 
CBDP+Sarin+Q-VD – 5 and CBDP+Sarin+Q-VE – 5. 
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Fig 19: AChE activity in frontal cortex at day 2 
The chart shows the effect of Q-VD-OPh and Q-VE-OPh on AChE activity in frontal 
cortex at day 2 (N = 14). Q-VD-OPh did not appear to have an inhibitory effect in mice 
treated with it and sarin. Q-VE-OPh also did not have a significant effect on sarin 
inhibition of acetylcholinesterase. 
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Discussion 
Inflammatory responses in the central and peripheral systems play an important 
role in the development of pathologies. Cytokines are proteins secreted by cells that have 
specific effects on the interactions between cells (Zhang & An, 2007). Cells throughout 
the body produce both pro-inflammatory cytokines and anti-inflammatory cytokines 
(Vexler & Yenari, 2009). This study is the first to evaluate more than 5 cytokines in 
specific brain regions, mainly due to expense and volume of sample. There were a 
number of questions to be answered in this study, the first set of which dealt with 
evaluating the control tissue for cytokine background. First it was important to determine  
what effect CBDP might have on the cytokines in the two brain regions. In this study, we 
found changes in several of the cytokine levels in the amygdala and hippocampus of 
CBDP treated animals at both 2 and 14 days.  There are no reports in the literature 
suggesting that CBDP may have an effect on cytokine levels or inflammation in the brain 
or other tissue. Our results are not definitive enough to differentiate what might have 
caused the cytokines to change following CBDP treatment. One possibility is thatthe 
decrease in carboxylesterase activity due to treatment of the mice with CBDP cause the 
cytokines to change, alternatively there could be a more direct effect of CBDP on the 
immune system that could cause cytokine changes. Searching the literature for CBDP 
revealed nothing that would suggest it had any type of inflammatory effect. However, it 
is a chemical and may elicit specific effects that are as yet undefined. Future experiments 
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with CBDP would explore this question in more detail. It would be interesting to know if 
there was a direct or indirect effect of CBDP on the immune system.  
The next question was whether Q-VD-OPh or Q-VE-OPh alone had any effect on 
the cytokines in the two brain regions. Again, we observed some cytokine changes in 
both 2 and 14 day amygdala and hippocampus due to either Q-VD-OPh or Q-VE-OPh. 
Q-VD-OPh is a caspase inhibitor and should not have a direct effect on the immune 
system. Q-VE-OPh has 50-100 fold less activity as a caspase inhibitor, making it a good 
negative control; and it too should not have an effect on cytokines. However, the results 
suggest that there was an effect with both. There can be several explanations. One is that 
these two compounds inhibit caspases and or caspase-dependent processes that could 
affect cytokine expression or secretion. Caspase 1 is involved in cleavage of immune 
proteins that elicit a strong neutrophil response suggesting that a caspase inhibitor could 
have an effect. Since Q-VE-OPh also had this effect, the effect may not have involved 
caspase inhibition. Alternatively, the two compounds could have a direct effect on the 
immune system by stimulating specific cytokines. Previous studies on inflammation and 
Q-VD-OPh suggest that it has the capacity to inhibit or attenuate activation of microglia 
and that its anti-apoptotic effects could mediate inflammatory responses (Venero, 
Burguillos, Brundin, & Joseph, 2011). Our results provide evidence supporting that 
previous study.  
The next phase of this project was to determine if sarin had an effect on cytokines. 
The results were unambiguous. Sarin had a significant effect on a majority of the 
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cytokines in the two brain regions at both 2 and 14 days. There have been limited reports 
of sarin affecting brain cytokines to date. In these studies on sarin or other 
organophosphates, a limited number of cytokines were evaluated, i.e., IL-1α, IL-1β, Il-6, 
TNFa and PGE2 (Angelini et al., 2013). For example, in a recent study from our lab, 
chlorpyrifos was found to cause an increase in IL-1β and TNFa (Rutherford, 2014). The 
introduction of the bead-based system that can analyze many more analytes in a very 
small volume of sample provides an excellent type of platform to study cytokines in 
sarin-treated animals. The results from our experiments are the first to show the effects of 
sarin on an expanded array of cytokines. Of interest was that cytokine levels appeared to 
decrease to a lower level in both tissues at 14 day, though some didn’t. These 23 
cytokines represent numerous pathways most of which have never been explored in 
previous studies on organophosphates. Future work should utilize expanded cytokine 
analysis with organophosphates and pathway analysis tools to build connections between 
the different cytokines and their expression or secretion. We have now established the 
background levels of the cytokines in the amygdala and hippocampal regions of mouse 
brain, 2 and 14 days after treatment with CBDP, Q-VD-OPh, and Q-VE-OPh. In addition 
we determined that sarin had a significant effect on cytokine levels at both time points. 
The next question was whether Q-VD-OPh could have an impact on any of these sarin-
induced cytokines in either of the tissues.  
The presence of Q-VD-OPh on cytokine values appeared to have a significant 
effect on 8 different cytokines in two day amygdala.The eight cytokines that significantly 
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decreased represent pro-and anti-inflammatory cytokines. The results show that Q-VD-
OPh does have an effect in preventing neuroinflammation due to sarin exposure. 
However, the effect is limited to amygdala only. By comparing the Q-VD-OPh results at 
2 and 14 days, we found that there was no prolonged effect of Q-VD-OPh. This is 
significant, because it suggested that Q-VD-OPh has a potentially shorter half-life and 
was most probably excreted in a few days from the body. Q-VE-OPh had no effect on 
sarin-induced cytokines further showing its usefulness as a negative-control inhibitor for 
Q-VD-OPh.  
Since Q-VD-OPh had an effect on cytokine levels following sarin exposure, the 
next question was whether Q-VD-OPh could have an effect on neurodegeneration. 
Neurodegeneration was detected by TUNEL assay. Sarin-induced seizures can cause both 
apoptosis and necrosis, though necrosis is believed to be the main route of cell death. 
Caspase mediated cleavage of caspase-activated DNase causes DNA fragmentation 
during apoptosis. This forms the characteristic internucleosomal DNA double strand 
breaks of 180-200 base pairs. Therefore, TUNEL positive cells that have undergone 
necrosis should appear as a lighter stain in the cells due to the presence of fragments (de 
Torres, Munell, Ferrer, Reventós, & Macaya, 1997; Stadelmann & Lassmann, 2000). 
When the brain sections in this study were stained for TUNEL, at 48 hours time point Q-
VD-OPh treated sections showed a lighter stain when compared to sarin and Q-VE-OPh 
treated sections. However, the result isn’t consistent for the14-day time point. At 14 days, 
there is not much observable difference in the Tunel staining of sections treated with 
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sarin, Q-VD-OPh and Q-VE-OPh. The probable explanation is that the prolonged effect 
of sarin does attenuate over time as fewer cells are adversely affected by the sarin. 
Furthermore, one injection of Q-VD-OPh is probably not enough to continue working 
after 14 days.  
The results from the apoptotic marker kit for analyzing 4 markers of apoptosis 
were ambiguous at best. The most important point to be made here is that we used frontal 
cortex tissue for this assay as the rest of the brain tissue had been used or discarded 
previously. In addition, active caspase 3 may have been generated early and then 
caspases could have been broken down prior to the two day time point that was tested as 
the first time point. This would explain the presence of very little caspase in the samples. 
Likewise, apoptosis may not have played a big role in the cell death and necrosis might 
have played a larger role. If this were the case, little caspase would be found and that also 
could explain the results. Future studies should preserve more tissue from the different 
brain regions to test for apoptotic markers.  
AChE activity, the hallmark of all OP studies was analyzed in frontal cortex tissue 
from these animals. While the results look interesting with Q-VD-OPh, these results were 
not significant mostly due to a lack of sample. The probability is that Q-VD-OPh did not 
have an effect on AChE activity. This is supported by the knowledge that AChE is a 
serine hydrolase while Q-VD-OPh inhibits aspartic proteases. Their mechanism is much 
different and casts doubt that this inhibitor would also have any effect on AChE. 
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However, future experiments should focus on this and analyze it with a larger sample size 
to determine if there was inhibition by Q-VD-OPh.   
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Conclusion 
Sarin is an OP ester that continues to be an active threat to military personnel and 
more importantly, a vulnerable civilian population. This study was focused on 
understanding the capability of a broad spectrum caspase inhibitor Q-VD-OPh to 
attenuate neurodegeneration and neuroinflammation in sarin exposed mice at two and 
fourteen day time points using cytokine analysis, TUNEL assay, apoptosis marker 
analysis and ccholinesterase activity analysis.  
Based on the observations and results obtained, it is clear that CBDP has variable 
effect on cytokines in the brain regions. In addition, there is also Q-VD-OPh and Q-VE-
OPh effect observed when administered in controls. Further work in this regards will be 
helpful in determining the exact cause of CBDP effect on cytokines. By analyzing vehicle 
and CBDP effect on cytokines, we were thus able to establish cytokine markers for sarin 
exposure. 
Sarin had a significant effect on majority of the examined cytokines at both the 
time points and also sarin causes neurodegeneration or cell death. Both amygdala and 
hippocampus showed large significant increases in most of the analyzed cytokines at two 
and fourteen day time points. This is indicative of the fact that OP exposures do lead to 
changes in the immune system causing increases in pro and anti-inflammatory cytokines. 
Sarin exposure effect is less at fourteen day time point in amygdala as compared to 
hippocampus. Also, sarin mostly causes increases in pro inflammatory cytokines than 
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anti inflammatory cytokines. Apoptosis marker analysis also indicates that sarin activates 
caspase-3, BCL and MCL, all three playing role in cell death regulation.  
The change in cytokines and reduction in TUNEL positive cells post Q-VD-OPh 
treatment suggests that Q-VD-OPh is effective in attenuating neuroinflammation and 
neurodegeneration in sarin exposed mice. Considering the fact that Q-VD-OPh effect was 
more pronounced in amygdala than hippocampus, we can conclude that Q-VD-OPh is 
effective as a caspase inhibitor only in specific brain regions or more precisely, in 
amygdala only. Also, cytokine analysis and TUNEL data reveal that Q-VD-OPh does not 
have prolonged effect on sarin exposed mice. Q-VD-OPh also did not have significant 
effect on inhibiton of AChE, the enzyme necessary for ACh breakdown, further 
suggesting target specificity of Q-VD-OPh towards caspases.  
Q-VE-OPh,  a negative control for Q-VD-OPh, did not have significant effect on 
sarin-induced cytokines. Also, TUNEL positive staining post Q-E-OPh treatment was 
similar to sarin treated brain sections. Q-VE-OPh showed enhanced positive staining as 
compared to Q-VD-OPh. This suggests further effectiveness of Q-VE-OPh as a negative 
control for Q-VD-OPh. 
Future research efforts would help to validate the neuroprotective effect of Q-VD-
OPh to attenuate neurodegeneration induced by OP exposures at a a shorter duration.  
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APPENDIX 
 
Table 1: Cytokine data for amygdala at day 2 comparing CBDP treated group with sarin-
treated group. The data represents protein concentration in pg/ml obtained by cytokine 
analysis. Significant data (p<0.05) is marked with *. Statistical significance was analyzed 
using 2-way ANOVA followed by Fisher LSD post hoc test. Data are expressed as mean 
± standard error. Shaded values represent significant change for respective cytokine. 
OOR: Out of range 
 
Glycol+Saline+
DMSO
Glycol+Saline+
Q-VE
Glycol+Saline+
Q-VD
CBDP+Saline+ 
DMSO
CBDP+Saline+ 
Q-VE
CBDP+Saline+ 
Q-VD
CBDP+SARIN
IL-1a 1.72 ± 0.22 1.22 ± 14.25 1.33 ± 0.25 1.48 ± 0.12 1.41 ± 0.26 1.03 ± 0.12 102.00 ± 0.00 *
IL-1b 56.59 ± 3.79 41.73 ± 4.72 47.09 ± 4.35 58.96 ± 1.40 63.44 ± 1.78 53.36 ± 2.07 169.42 ± 30.89 *
IL-2 8.00 ± 0.64 6.43 ± 1.18 6.96 ± 1.10 9.40 ± 0.34 8.64 ± 0.66 8.16 ± 0.50 10.08 ± 2.23 *
IL-3 0.72 ± 0.17 14.78 ± 14.37 0.41 ± 0.15 1.31 ± 0.08 1.23 ± 0.13 1.09 ± 0.13 4.50 ± 1.19
IL-4 OOR OOR OOR OOR OOR OOR 35.33 ± 33.33
IL-5 3.24 ± 0.47 16.12 ± 14.15 2.19 ± 0.35 3.75 ± 0.22 3.34 ± 0.54 2.79 ± 0.37 6.27 ± 2.73
IL-6 0.90 ± 0.14 0.85 ± 0.14 15.40 ± 14.27 1.05 ± 0.09 1.02 ± 0.21 0.92 ± 0.10 4.14 ± 1.68
IL-9 127.35 ± 33.19 106 ± 19.72 147.75 ± 20.89 187.11 ± 12.81 179.46 ± 16.93 138.39 ± 23.45 102.00 ± 0.00 *
IL-10 10.56 ± 1.43 6.77 ± 1.59 7.39 ± 1.50 14.71 ± 0.72 15.64 ± 0.77 11.48 ± 1.11 21.50 ± 6.34 *
IL-12(p40) 9.34 ± 1.88 4.75 ± 0.98 6.45 ± 1.21 10.11 ± 0.61 8.85 ± 1.25 9.20 ± 1.15 7.09 ± 1.05
IL-12(p70) 24.34 ± 1.35 19.31 ± 3.04 23.49 ± 4.13 32.15 ± 1.77 25.67 ± 2.76 27.55 ± 3.84 101.66 ± 0.33 *
IL-13 96.20 ± 10.13 73.78 ± 9.29 74.33 ± 10.51 110.09 ± 3.78 125.01 ± 4.50 93.14 ± 5.29 394.55 ± 124. 69 *
IL-17 19.75 ± 1.45 22.75 ± 3.52 21.78 ± 3.88 21.33 ± 1.32 23.97 ± 2.87 23.09 ± 1.69 36.95 ± 18.62 *
Eotaxin 99.24 ± 13.73 107.00 ± 11.70 115.31 ± 6.51 121.87 ± 9.47 119.10 ± 18.67 150.26 ± 10.22 254.70 ± 63.11 *
G-CSF OOR OOR OOR OOR OOR OOR 3.92 ± 1.93
GM-CSF 28.29 ± 6.13 32.91 ± 11.55 62.00 ± 13.89 35.92 ± 2.76 24.96 ± 4.81 35.66 ± 4.63 61.38 ± 20.29 *
IFN-g 9.55 ± 1.56 6.70 ± 1.32 9.64 ± 1.61 13.93 ± 1.22 8.96 ± 1.80 13.55 ± 5.08 2.36 ± 1.38 *
KC 4.39 ± 0.58 2.56 ± 0.42 3.72 ± 0.68 5.72 ± 0.26 6.28 ± 0.13 5.14 ± 0.44 10.98 ± 9.58 *
MCP-1 21.30 ± 3.48 12.49 ± 2.34 15.17 ± 3.64 26.79 ± 0.95 28.64 ± 1.47 22.81 ± 1.85 85.62 ± 31.30 *
MIP-1a 52.74 ± 27.86 33.37 ± 17.77 61.47 ± 18.77 101.00 ± 0.00 101.00 ± 0.00 101.00 ± 0.00 102.00 ± 0.57 *
MIP-1b 23.16 ± 4.16 21.20 ± 2.33 24.59 ± 3.84 18.38 ± 1.25 14.23 ± 0.67 17.21 ± 1.74 46.75 ± 5.76 *
Rantes 1.37 ± 0.42 15.52 ± 14.25 15.99 ± 14.17 3.81 ± 0.34 3.48 ± 0.41 4.25 ± 0.50 3.94 ± 1.78
TNF-a 225.90 ± 14.35 191.80 ± 19.31 219.98 ± 21.02 250.71 ± 6.97 239.71 ± 13.42 230.73 ± 15.97 123.38 ± 24.98 *
Cytokine
AMY 2 DAY
 
73 
 
 
Table 2: Cytokine data for hippocampus at day 2 comparing CBDP treated group with 
sarin-treated group. The data represents protein concentration in pg/ml obtained by 
cytokine analysis. Significant data (p<0.05) is marked with *. Statistical significance was 
analyzed using 2-way ANOVA followed by Fisher LSD post hoc test. Data are expressed 
as mean ± standard error. Shaded values represent significant change for respective 
cytokine. 
OOR: Out of range 
Glycol+Saline+
DMSO
Glycol+Saline+
Q-VE
Glycol+Saline+
Q-VD
CBDP+Saline+ 
DMSO
CBDP+Saline+ 
Q-VE
CBDP+Saline+ 
Q-VD
CBDP+SARIN
IL-1a 1.35 ± 0.23 15.19 ± 14.30 15.12 ± 14.32 60.79 ± 16.41 50.71 ± 29.03 29.01 ± 15.58 80.83 ± 20.16 *
IL-1b 20.53 ± 3.14 21.71 ± 1.53 20.67 ± 1.31 13.23 ± 1.72 16.29 ± 1.61 21.45 ± 1.17 107.39 ± 42.28 *
IL-2 1.41 ± 0.21 1.13 ± 0.07 1.33 ± 0.10 50.92 ± 16.69 0.85 ± 0.28 15.64 ± 14.22 6.96 ± 1.36 *
IL-3 101.00 ± 0.00 101.00 ± 0.00 101.00 ± 0.00 101.00 ± 0.00 101.00 ± 0.00 57.88 ± 20.32 1.11 ± 0.29
IL-4 0.48 ± 0.07 0.39 ± 0.03 0.41 ± 0.02 0.28 ± 0.03 0.33 ± 0.03 0.58 ± 0.10 1.54 ± 0.30 *
IL-5 1.37 ± 0.12 1.25 ± 0.07 1.14 ± 0.08 0.71 ± 0.12 0.94 ± 0.11 1.30 ± 0.15 103.00 ± 0.71 *
IL-6 0.38 ± 0.12 0.30 ± 0.05 0.26 ± 0.04 50.56 ± 16.81 0.06 ± 0.03 14.54 ± 14.41 2.24 ± 0.66 *
IL-9 46.40 ± 4.15 44.81 ± 3.88 37.53 ± 2.88 62.70 ± 12.90 27.33 ± 6.85 32.98 ± 6.06 75.90 ± 20.22 *
IL-10 3.94 ± 0.28 3.05 ± 0.29 2.92 ± 0.21 1.37 ± 0.34 2.22 ± 0.21 3.86 ± 0.81 7.088 ± 1.93 *
IL-12(p40) 2.58 ± 0.69 3.30 ± 0.80 2.32 ± 0.33 1.31 ± 0.17 2.14 ± 0.61 2.59 ± 0.44 23.09 ± 19.49 *
IL-12(p70) 8.50 ± 1.22 7.09 ± 0.51 7.23 ± 0.44 22.81 ± 13.04 4.53 ± 0.40 7.41 ± 1.41 101.00 ± 0.00
IL-13 25.69 ± 2.62 27.83 ± 2.17 28.23 ± 1.79 15.83 ± 2.35 21.32 ± 3.39 26.82 ± 3.68 28.71 ± 6.66 *
IL-17 5.78 ± 0.21 5.65 ± 0.20 5.54 ± 0.27 3.17 ± 0.49 5.06 ± 0.73 5.51 ± 0.54 9.06 ± 1.37 *
Eotaxin 79.68 ± 21.31 50.53 ± 17.88 52.29 ± 17.56 91.98 ± 9.01 101.00 ± 0.00 63.31 ± 17.92 231.35 ± 83.88 *
G-CSF 0.25 ± 0.09 0.22 ± 0.05 0.26 ± 0.07 50.57 ± 16.80 25.28 ± 25.23 29.26 ± 18.52 83.75 ± 18.75 *
GM-CSF 80.57 ± 20.43 63.40 ± 17.75 64.33 ± 17.30 83.66 ± 11.56 101.00 ± 0.00 67.74 ± 15.85 84.31 ± 16.69
IFN-g 2.79 ± 0.15 2.57 ± 0.16 2.75 ± 0.10 2.14 ± 0.15 1.86 ± 0.25 3.47 ± 0.53 24.00 ± 19.33 *
KC 1.73 ± 0.15 1.43 ± 0.13 2.72 ± 0.72 1.25 ± 0.20 2.00 ± 0.81 2.14 ± 0.42 68.07 ± 43.98 *
MCP-1 7.00 ± 0.75 5.91 ± 0.38 8.25 ± 1.03 5.60 ± 1.67 5.64 ± 1.40 7.72 ± 1.45 41.58 ± 29.53 *
MIP-1a 3.71 ± 1.23 4.26 ± 1.21 2.24 ± 0.77 11.44 ± 9.96 1.32 ± 0.62 29.87 ± 18.37 63.67 ± 23.06 *
MIP-1b 9.43 ± 0.95 10.62 ± 0.60 9.98 ± 0.74 17.44 ± 3.00 9.52 ± 0.91 8.78 ± 1.25 16.73 ± 6.30
Rantes 0.71 ± 0.13 1.44 ± 0.62 0.92 ± 0.13 1.13 ± 0.30 0.76 ± 0.20 2.75 ± 0.81 1.53 ± 0.36
TNF-a 40.00 ± 2.94 37.95 ± 2.53 36.38 ± 1.28 24.80 ± 3.44 34.20 ± 1.44 44.27 ± 5.44 133.37 ± 16.55 *
Cytokine
HIPPO 2 DAY
 
74 
 
 
Table 3: Cytokine data for amygdala at day 2 comparing sarin-treated group with Q-VD-
OPh and Q-VE-OPh treated groups. The data represents protein concentration in pg/ml 
obtained by cytokine analysis. Significant data (p<0.05) is marked with *. Statistical 
significance was analyzed using 2-way ANOVA followed by Fisher LSD post hoc test. 
Data are expressed as mean ± standard error. Shaded values represent significant change 
for respective cytokine. Also compared here are diazepam treated groups for reference 
purpose. 
OOR: Out of range 
 
CBDP+SARIN
CBDP+SARIN+ 
Q-VD
CBDP+SARIN+ 
Q-VE
CBDP+SARIN+ 
DIA
CBDP+SARIN+ 
DIA+Q-VD
CBDP+SARIN+ 
DIA+Q-VE
IL-1a OOR OOR OOR OOR OOR OOR
IL-1b 169.42 ± 30.89 97.76 ± 15.11 * 139.93 ± 12.86 1.84 ± 0.30 * 114.88 ± 8.50 * 106.23 ± 11.22 *
IL-2 10.08 ± 2.23 7.23 ± 0.69 * 8.82 ± 0.51 7.78 ± 1.03 8.61 ± 0.25 7.30 ± 0.63
IL-3 4.50 ± 1.19 2.04 ± 0.43 * 3.85 ± 0.73 1.80 ± 0.48 * 2.49 ± 0.28 * 2.09 ± 0.41 *
IL-4 OOR OOR OOR OOR OOR OOR
IL-5 6.27 ± 2.73 2.30 ± 0.90 6.17 ± 1.47 1.94 ± 1.39 3.95 ± 0.83 3.60 ± 0.73
IL-6 4.14 ± 1.68 2.28 ± 0.44 3.83 ± 0.52 2.21 ± 0.58 2.85 ± 0.27 2.54 ± 0.36
IL-9 OOR OOR OOR OOR OOR OOR
IL-10 21.50 ± 6.34 12.21 ± 2.18 * 19.30 ± 2.60 11.03 ± 2.52 * 15.96 ± 1.20 12.89 ± 1.66
IL-12(p40) 7.09 ± 1.05 3.99 ± 0.77 * 5.88 ± 0.83 3.92 ± 0.54 * 4.80 ± 0.22 4.00 ± 0.43 *
IL-12(p70) 101.66 ± 0.33 103.00 ± 0.52 103.80 ± 1.11 102.00 ± 0.00 105.25 ± 1.89 88.21 ± 22.80
IL-13 394.55 ± 124. 69 210.94 ± 45.97 * 360.31 ± 53.08 205.89 ± 50.44 272.55 ± 20.02 242.76 ± 33.58
IL-17 36.95 ± 18.62 18.60 ± 5.35 32.94 ± 5.99 15.30 ± 6.79 25.74 ± 2.83 22.07 ± 4.79
Eotaxin 254.70 ± 63.11 219.06 ± 33.46 223.76 ± 27.15 294.83 ± 67.30 175.45 ± 42.17 224.20 ± 42.11
G-CSF 3.92 ± 1.93 1.93 ± 0.53 5.61 ± 1.42 1.14 ± 0.72 2.03 ± 0.43 1.71 ± 0.37
GM-CSF 61.38 ± 20.29 53.58 ± 11.63 58.64 ± 5.95 37.79 ± 10.56 43.02 ± 4.99 35.43 ± 10.77
IFN-g 2.36 ± 1.38 18.00 ± 16.60 2.18 ± 0.49 1.48 ± 1.03 1.66 ± 0.94 1.89 ± 0.84
KC 10.98 ± 9.58 1.34 ± 0.20 6.29 ± 3.94 1.03 ± 0.21 1.35 ± 0.21 0.89 ± 0.28
MCP-1 85.62 ± 31.30 44.70 ± 9.92 86.19 ± 17.59 32.37 ± 17.13 52.71 ± 8.43 36.63 ± 9.03
MIP-1a 102.00 ± 0.57 88.71 ± 16.90 107.00 ± 0.63 109.00 ± 1.53 84.50 ± 25.87 115.50 ± 0.65
MIP-1b 46.75 ± 5.76 26.62 ± 4.83 * 36.82 ± 3.38 33.00 ± 0.92 31.19 ± 3.52 * 27.65 ± 2.05 *
Rantes 3.94 ± 1.78 1.48 ± 0.43 3.28 ± 0.78 1.76 ± 0.24 2.00 ± 0.42 26.73 ± 24.76
TNF-a 123.38 ± 24.98 72.26 ± 11.95 * 98.80 ± 5.69 83.80 ± 21.96 95.50 ± 11.60 88.41 ± 11.50
Cytokine
AMY 2 DAY
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Table 4: Cytokine data for hippocampus at day 2 comparing sarin-treated group with Q-
VD-OPh and Q-VE-OPh treated groups. The data represents protein concentration in 
pg/ml obtained by cytokine analysis. Significant data (p<0.05) is marked with *. 
Statistical significance was analyzed using 2-way ANOVA followed by Fisher LSD post 
hoc test. Data are expressed as mean ± standard error. Shaded values represent significant 
change for respective cytokine. Also compared here are diazepam treated groups for 
reference purpose. 
OOR: Out of range 
 
 
CBDP+SARIN
CBDP+SARIN+ 
Q-VD
CBDP+SARIN+ 
Q-VE
CBDP+SARIN+ 
DIA
CBDP+SARIN+ 
DIA+Q-VD
CBDP+SARIN+ 
DIA+Q-VE
IL-1a 80.83 ± 20.16 101.00 ± 0.00 101.00 ± 0.00 101.00 ± 0.00 101.00 ± 0.00 101.00 ± 0.00
IL-1b 107.39 ± 42.28 107.08 ± 15.12 106.46 ± 16.80 43.65 ± 9.75 136.54 ± 31.49 84.63 ± 22.21
IL-2 6.96 ± 1.36 7.84 ± 0.69 7.66 ± 1.12 4.43 ± 0.79 9.62 ± 2.01 7.99 ± 1.70
IL-3 1.11 ± 0.29 1.12 ± 0.14 1.13 ± 0.15 0.58 ± 0.12 1.43 ± 0.20 1.01 ± 0.22
IL-4 1.54 ± 0.30 1.74 ± 0.15 1.66 ± 0.19 1.04 ± 0.15 2.04 ± 0.25 1.53 ± 0.29
IL-5 103.00 ± 0.71 108.50 ± 0.76 114.50 ± 0.76 * 119.00 ± 0.57 * 118.00 ± 4.02 * 115.50 ± 5.39 *
IL-6 2.24 ± 0.66 2.15 ± 0.18 19.26 ± 16.35 1.05 ± 0.15 2.24 ± 0.23 1.69 ± 0.32
IL-9 75.90 ± 20.22 63.36 ± 5.97 70.26 ± 11.00 38.15 ± 6.14 91.22 ± 22.41 63.97 ± 12.07
IL-10 7.088 ± 1.93 6.81 ± 0.43 6.51 ± 1.01 3.26 ± 0.63 7.77 ± 1.29 6.53 ± 1.28
IL-12(p40) 23.09 ± 19.49 20.54 ± 16.30 3.79 ± 0.41 35.73 ± 33.63 3.45 ± 0.86 3.73 ± 0.85
IL-12(p70) 101.00 ± 0.00 84.72 ± 16.28 101.00 ± 0.00 101.00 ± 0.00 101.00 ± 0.00 101.00 ± 0.00
IL-13 28.71 ± 6.66 48.23 ± 9.62 46.01 ± 10.71 17.19 ± 2.71 72.10 ± 11.06 * 54.95 ± 18.51
IL-17 9.06 ± 1.37 15.54 ± 2.29 14.66 ± 4.35 8.86 ± 1.31 15.34 ± 1.55 12.66 ± 2.60
Eotaxin 231.35 ± 83.88 184.50 ± 36.93 119.47 ± 40.86 102.00 ± 39.55 152.82 ± 48.04 304.60 ± 119.56
G-CSF 83.75 ± 18.75 97.82 ± 9.19 68.02 ± 19.40 114.00 ± 0.57 117.50 ± 0.65 121.50 ± 0.65
GM-CSF 84.31 ± 16.69 75.59 ± 16.07 88.59 ± 12.41 101.00 ± 0.00 101.00 ± 0.00 101.00 ± 0.00
IFN-g 24.00 ± 19.33 37.26 ± 20.63 21.01 ± 16.61 36.65 ± 34.17 55.28 ± 29.56 4.29 ± 1.07
KC 68.07 ± 43.98 29.92 ± 15.60 43.61 ± 30.43 6.19 ± 1.25 30.63 ± 24.15 4.75 ± 0.64
MCP-1 41.58 ± 29.53 22.73 ± 10.08 64.27 ± 25.51 7.08 ± 1.63 35.47 ± 21.91 15.60 ± 5.13
MIP-1a 63.67 ± 23.06 89.10 ± 12.90 58.01 ± 20.64 103.00 ± 2.00 76.73 ± 24.65 107.00 ± 2.04
MIP-1b 16.73 ± 6.30 15.94 ± 2.14 18.83 ± 4.73 5.69 ± 1.29 28.74 ± 12.65 15.54 ± 5.02
Rantes 1.53 ± 0.36 2.40 ± 0.80 4.81 ± 1.85 1.67 ± 0.37 5.82 ± 3.96 3.33 ± 0.37
TNF-a 133.37 ± 16.55 148.92 ± 14.84 124.11 ± 10.02 92.63 ± 12.81 132.39 ± 10.05 169.42 ± 18.43
Cytokine
HIPPO 2 DAY
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Table 5: Cytokine data for amygdala at day 14 comparing CBDP treated group with 
sarin-treated group. The data represents protein concentration in pg/ml obtained by 
cytokine analysis. Significant data (p<0.05) is marked with *. Statistical significance was 
analyzed using 2-way ANOVA followed by Fisher LSD post hoc test. Data are expressed 
as mean ± standard error. Shaded values represent significant change for respective 
cytokine. 
OOR: Out of range 
Glycol+Saline+
DMSO
Glycol+Saline+
Q-VE
Glycol+Saline+
Q-VD
CBDP+Saline+ 
DMSO
CBDP+Saline+ 
Q-VE
CBDP+Saline+ 
Q-VD
CBDP+SARIN
IL-1a 25.44 ± 25.19 14.71 ± 14.38 43.37 ± 20.38 30.43 ± 15.40 25.52 ± 25.16 86.57 ± 14.43 67.55 ± 21.15
IL-1b 101.00 ± 0.00 86.65 ± 14.35 101.00 ± 0.00 101.00 ± 0.00 76.19 ± 24.81 101.00 ± 0.00 90.37 ± 30.26
IL-2 OOR < OOR < OOR < OOR < OOR < OOR < 10.05 ± 3.32
IL-3 OOR < OOR < OOR < OOR < OOR < OOR < 34.27 ± 21.02
IL-4 OOR < OOR < OOR < OOR < OOR < OOR < 3.16 ± 1.11
IL-5 26.47 ± 24.84 30.34 ± 18.25 58.28 ± 20.14 11.83 ± 9.91 27.52 ± 24.51 44.03 ± 20.14 3.66 ± 1.41 *
IL-6 OOR < OOR < OOR < OOR < OOR < OOR < 2.90 ±  0.92
IL-9 79.08 ± 21.92 75.73 ± 16.33 77.50 ± 50.18 67.32 ± 13.90 64.15 ± 21.57 101.00 ± 0.00 OOR <
IL-10 0.93 ± 0.08 57.84 ± 20.34 58.02 ± 20.26 31.10 ± 15.26 1.94 ± 0.58 86.69 ± 14.30 14.79 ± 5.43 *
IL-12(p40) 101.00 ± 0.00 101.00 ± 0.00 101.00 ± 0.00 100.01 ± 1.00 104.03 ± 3.03 101.00 ± 0.00 5.73 ± 1.69 *
IL-12(p70) OOR < OOR < OOR < OOR < OOR < OOR < 84.19 ± 16.81
IL-13 29.51 ± 10.08 11.61 ± 2.10 12.82 ± 3.38 17.87 ± 3.06 30.79 ± 4.12 25.28 ± 12.75 275.19 ± 99.22 *
IL-17 189.72 ± 30.52 116.74 ± 6.53 113.14 ± 14.26 105.45 ± 4.86 145.88 ± 23.56 115.05 ± 7.72 31.88 ± 10.51 *
Eotaxin OOR < OOR < OOR < OOR < OOR < OOR < 87.14 ± 13.13
G-CSF 75.86 ± 25.14 101.00 ± 0.00 101.00 ± 0.00 101.00 ± 0.00 75.75 ± 25.24 101.00 ± 0.00 3.77 ± 1.38 *
GM-CSF OOR < OOR < OOR < OOR < OOR < OOR < 45.37 ± 17.79
IFN-g 1.78 ± 0.18 2.28 ± 0.12 2.10 ± 0.11 2.54 ± 0.15 2.75 ± 0.47 2.37 ± 0.20 51.36 ± 22.21 *
KC OOR < OOR < OOR < OOR < OOR < OOR < 2.37 ± 0.63
MCP-1 33.75 ± 22.72 59.29 ± 19.66 61.45 ± 18.70 18.61 ± 9.30 15.21 ± 4.37 46.49 ± 19.27 47.58 ± 17.31
MIP-1a OOR < OOR < OOR < OOR < OOR < OOR < 84.42 ± 16.58
MIP-1b 2.08 ± 0.80 1.06 ± 0.21 0.89 ± 0.33 0.99 ± 0.22 1.28 ± 0.71 29.43 ± 18.48 32.47 ± 7.97 *
Rantes 0.44 ± 0.20 0.24 ± 0.05 14.91 ± 14.35 1.95 ± 0.34 3.78 ± 1.49 44.35 ± 20.03 2.00 ± 0.67 *
TNF-a 501.25 ± 55.11 496.63 ± 51.28 359.86 ± 87.85 481.26 ± 59.56 674.55 ± 149.53 251.15 ± 52.63 127.55 ± 30.00 *
Cytokine
AMY 14 DAY
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Table 6: Cytokine data for hippocampus at day 14 comparing CBDP treated group with 
sarin-treated group. The data represents protein concentration in pg/ml obtained by 
cytokine analysis. Significant data (p<0.05) is marked with *. Statistical significance was 
analyzed using 2-way ANOVA followed by Fisher LSD post hoc test. Data are expressed 
as mean ± standard error. Shaded values represent significant change for respective 
cytokine. 
OOR: Out of range 
 
Glycol+Saline+
DMSO
Glycol+Saline+
Q-VE
Glycol+Saline+
Q-VD
CBDP+Saline+ 
DMSO
CBDP+Saline+ 
Q-VE
CBDP+Saline+ 
Q-VD
CBDP+SARIN
IL-1a 25.46 ± 25.18 29.17 ± 18.54 14.94 ± 14.34 21.04 ± 13.33 0.87 ± 0.38 57.92 ± 20.30 101.00 ± 0.00
IL-1b 13.32 ± 2.79 14.18 ± 2.02 50.98 ± 21.43 61.46 ± 20.53 75.20 ± 31.22 19.34 ± 3.66 102.48 ± 14.00 *
IL-2 0.55 ± 0.12 14.98 ± 14.33 2.88 ± 0.85 2.79 ± 0.97 3.07 ± 1.06 1.12 ± 0.34 21.35 ± 5.00 *
IL-3 101.00 ± 0.00 101.00 ± 0.00 86.82 ± 14.17 71.72 ± 14.91 52.33 ± 28.09 72.42 ± 18.44 5.95 ± 0.64 *
IL-4 0.88 ± 0.02 0.91 ± 0.05 1.29 ± 0.18 1.65 ± 0.24 1.81 ± 0.35 1.20 ± 0.13 3.89 ± 0.35 *
IL-5 1.21 ± 0.17 0.99 ± 0.22 1.55 ± 0.42 1.79 ± 0.36 1.67 ± 0.28 0.91 ± 0.10 3.77 ± 0.45 *
IL-6 101.00 ± 0.00 86.58 ± 14.41 72.40 ± 18.45 61.07 ± 16.30 50.98 ± 28.87 101.00 ± 0.00 4.28 ± 0.62 *
IL-9 101.00 ± 0.00 89.80 ± 11.19 90.36 ± 10.63 90.07 ± 9.64 84.76 ± 16.23 101.00 ± 0.00 OOR
IL-10 2.06 ± 0.95 17.02 ± 14.01 5.62 ± 2.33 7.15 ± 1.98 8.01 ± 2.61 30.84 ± 18.12 17.21 ± 1.82
IL-12(p40) 1.73 ± 0.68 1.53 ± 0.67 1.67 ± 0.56 4.05 ± 1.01 5.79 ± 1.58 1.74 ± 0.48 12.83 ± 0.53 *
IL-12(p70) 2.11 ± 1.02 32.01 ± 17.85 31.41 ± 17.98 12.15 ± 9.89 1.40 ± 0.52 58.00 ± 20.26 18.25 ± 3.34 
IL-13 25.45 ± 5.26 28.49 ± 6.25 60.67 ± 18.99 72.17 ± 16.40 86.43 ± 30.39 28.85 ± 6.37 167.84 ± 21.43 *
IL-17 7.06 ± 1.34 6.73 ± 0.99 7.59 ± 0.50 7.47 ± 1.06 6.12 ± 0.94 3.74 ± 0.36 32.97 ± 2.75 *
Eotaxin 101.00 ± 0.00 91.67 ± 9.32 231.20 ± 100.98 393.21 ± 149.07 395.01 ± 193.31 81.15 ± 12.98 243.44 ± 51.31
G-CSF 101.00 ± 0.00 101.00 ± 0.00 16.33 ± 14.16 12.66 ± 9.87 2.60 ± 1.22 43.67 ± 20.26 2.75 ± 0.42 *
GM-CSF 52.61 ± 27.93 59.13 ± 19.73 73.56 ± 17.71 72.70 ± 14.41 76.48 ± 24.51 101.00 ± 0.00 45.17 ± 8.68 *
IFN-g 1.27 ± 0.37 0.99 ± 0.26 0.88 ± 0.31 1.38 ± 0.35 1.51 ± 0.37 15.04 ± 14.32 9.12 ± 0.93
KC 1.07 ± 0.37 0.79 ± 0.17 1.74 ± 0.59 2.65 ± 0.51 3.96 ± 1.44 1.19 ± 0.25 7.78 ± 0.72 *
MCP-1 4.87 ± 1.18 18.14 ± 13.81 10.57 ± 3.09 13.26 ± 3.12 15.37 ± 4.14 6.03 ± 1.32 35.94 ± 3.61
MIP-1a 101.00 ± 0.00 101.00 ± 0.00 101.00 ± 0.00 71.14 ± 15.20 101.00 ± 0.00 101.00 ± 0.00 7.43 ± 1.56
MIP-1b 3.80 ± 0.88 3.63 ± 0.56 5.38 ± 1.60 7.36 ± 1.94 6.58 ± 2.07 3.39 ± 0.73 86.94 ± 31.45
Rantes 0.63 ± 0.27 14.70 ± 14.38 1.14 ± 0.37 2.07 ± 0.56 3.02 ± 1.20 15.58 ± 14.24 5.80 ± 0.63
TNF-a 28.08 ± 5.10 28.44 ± 3.24 40.56 ± 7.93 53.25 ± 11.26 65.46 ± 17.43 32.07 ± 2.83 248.2 ± 53.3
Cytokine
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Table 7: Cytokine data for amygdala at day 14 comparing sarin-treated group with Q-
VD-OPh and Q-VE-OPh treated groups. The data represents protein concentration in 
pg/ml obtained by cytokine analysis. Significant data (p<0.05) is marked with *. 
Statistical significance was analyzed using 2-way ANOVA followed by Fisher LSD post 
hoc test. Data are expressed as mean ± standard error. Shaded values represent significant 
change for respective cytokine. Also compared here are diazepam treated groups for 
reference purpose. 
OOR: Out of range 
CBDP+SARIN
CBDP+SARIN+ 
Q-VD
CBDP+SARIN+ 
Q-VE
CBDP+SARIN+ 
DIA
CBDP+SARIN+ 
DIA+Q-VD
CBDP+SARIN+ 
DIA+Q-VE
IL-1a 67.55 ± 21.15 101.00 ± 0.00 67.37 ± 12.70 50.61 ± 29.09 80.89 ± 20.11 50.70 ± 22.50
IL-1b 90.37 ± 30.26 88.75 ± 24.58 69.47 ± 12.64 81.30 ± 24.31 70.25 ± 5.79 60.19 ± 7.52
IL-2 10.05 ± 3.32 9.88 ± 2.70 6.89 ± 0.69 7.15 ± 0.82 6.00 ± 0.63 7.14 ± 0.59
IL-3 34.27 ± 21.02 21.58 ± 19.87 35.13 ± 20.83 52.97 ± 27.75 21.35 ± 19.92 17.57 ± 16.69
IL-4 3.16 ± 1.11 3.19 ± 1.06 2.35 ± 0.39 2.77 ± 0.84 2.36 ± 3.17 1.85 ± 0.20
IL-5 3.66 ± 1.41 3.95 ± 1.75 3.39 ± 0.78 3.96 ± 1.85 3.57 ± 0.63 2.70 ± 0.47
IL-6 2.90 ±  0.92 3.24 ± 0.99 2.63 ± 0.48 3.04 ± 0.91 2.76 ± 0.30 2.60 ± 0.40
IL-9 OOR < OOR < OOR < OOR < OOR < OOR <
IL-10 14.79 ± 5.43 14.38 ± 5.13 14.46 ± 2.15 14.07 ± 6.31 12.33 ± 2.25 10.56 ± 1.82
IL-12(p40) 5.73 ± 1.69 6.07 ± 1.45 4.86 ± 0.73 5.45 ± 1.66 5.15 ± 0.25 4.45 ± 0.34
IL-12(p70) 84.19 ± 16.81 44.34 ± 23.31 51.10 ± 22.32 82.61 ± 18.39 82.42 ± 18.58 36.47 ± 20.42
IL-13 275.19 ± 99.22 276.15 ± 101.89 249.19 ± 57.44 279.88 ± 90.53 257.66 ± 41.20 212.36 ± 32.89
IL-17 31.88 ± 10.51 30.62 ± 9.60 29.24 ± 4.47 32.46 ± 7.38 33.83 ± 4.18 30.55 ± 3.40
Eotaxin 87.14 ± 13.13 82.39 ± 22.62 75.09 ± 13.76 95.74 ± 25.83 70.97 ± 24.44 58.11 ± 4.82
G-CSF 3.77 ± 1.38 3.99 ± 2.04 3.47 ± 1.02 4.35 ± 2.73 3.41 ± 0.86 2.88 ± 0.59
GM-CSF 45.37 ± 17.79 41.59 ± 16.59 48.55 ± 17.13 69.58 ± 20.01 14.03 ± 3.46 10.62 ± 3.46
IFN-g 51.36 ± 22.21 42.23 ± 24.01 18.01 ± 16.60 27.50 ± 24.50 1.30 ± 0.24 * 1.41 ± 0.23 *
KC 2.37 ± 0.63 2.61 ± 0.79 2.34 ± 0.39 2.51 ± 0.93 2.32 ± 0.34 2.02 ± 0.60
MCP-1 47.58 ± 17.31 47.51 ± 21.49 43.89 ± 11.36 50.37 ± 23.86 42.78 ± 8.11 36.71 ± 5.88
MIP-1a 84.42 ± 16.58 60.94 ± 24.53 84.23 ± 16.76 51.28 ± 28.71 81.06 ± 19.94 84.20 ± 16.80
MIP-1b 32.47 ± 7.97 42.58 ± 8.47 20.73 ± 1.26 28.23 ± 6.12 23.36 ± 4.08 20.29 ± 1.68
Rantes 2.00 ± 0.67 2.44 ± 0.76 2.13 ± 0.31 2.84 ± 0.95 2.63 ± 0.52 2.33 ± 0.23
TNF-a 127.55 ± 30.00 151.55 ± 48.58 93.26 ± 10.67 101.24 ± 20.00 82.21 ± 8.39 77.55 ± 4.56
Cytokine
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Table 8: Cytokine data for hippocampus at day 14 comparing sarin-treated group with Q-
VD-OPh and Q-VE-OPh treated groups. The data represents protein concentration in 
pg/ml obtained by cytokine analysis. Significant data (p<0.05) is marked with *. 
Statistical significance was analyzed using 2-way ANOVA followed by Fisher LSD post 
hoc test. Data are expressed as mean ± standard error. Shaded values represent significant 
change for respective cytokine. Also compared here are diazepam treated groups for 
reference purpose. 
OOR: Out of range 
 
 
CBDP+SARIN
CBDP+SARIN+ 
Q-VD
CBDP+SARIN+ 
Q-VE
CBDP+SARIN+ 
DIA
CBDP+SARIN+ 
DIA+Q-VD
CBDP+SARIN+ 
DIA+Q-VE
IL-1a 101.00 ± 0.00 80.85 ± 20.15 101.00 ± 0.00 101.00 ± 0.00 101.00 ± 0.00 84.21 ± 16.78
IL-1b 102.48 ± 14.00 62.09 ± 9.43 95.95 ± 19.62 93.64 ± 13.39 80.22 ± 15.21 95.60 ± 17.48
IL-2 21.35 ± 5.00 11.70 ± 1.77 23.37 ± 1.94 27.27 ± 4.35 23.38 ± 4.03 26.97 ± 3.77
IL-3 5.95 ± 0.64 3.98 ± 0.53 3.55 ± 0.53 * 4.81 ± 0.39 4.67 ± 1.09 4.70 ± 0.81
IL-4 3.89 ± 0.35 2.95 ± 0.33 3.68 ± 0.46 3.60 ± 0.45 3.22 ± 0.52 3.86 ± 0.39
IL-5 3.77 ± 0.45 2.72 ± 0.25 3.48 ± 0.45 3.15 ± 0.45 2.86 ± 0.66 3.29 ± 0.65
IL-6 4.28 ± 0.62 2.83 ± 0.40 4.27 ± 0.65 3.74 ± 0.55 3.56 ± 0.77 4.53 ± 0.72
IL-9 OOR OOR OOR OOR OOR OOR
IL-10 17.21 ± 1.82 13.94 ± 2.27 15.74 ± 2.13 15.16 ± 1.85 12.77 ± 2.09 14.35 ± 2.85
IL-12(p40) 12.83 ± 0.53 12.27 ± 1.22 10.15 ± 0.31 15.83 ± 3.84 9.50 ± 1.39 9.91 ± 1.33
IL-12(p70) 18.25 ± 3.34 31.30 ± 17.48 25.55 ± 15.22 39.97 ± 20.68 14.63 ± 5.89 26.43 ± 15.14
IL-13 167.84 ± 21.43 147.35 ± 21.32 176.51 ± 20.46 170.06 ± 24.54 154.24 ± 33.89 188.67 ± 32.70
IL-17 32.97 ± 2.75 32.94 ± 2.78 35.49 ± 3.23 42.14 ± 4.36 34.50 ± 4.15 40.92 ± 3.38
Eotaxin 243.44 ± 51.31 278.04 ± 64.65 160.95 ± 21.87 217.67 ± 30.39 174.04 ± 55.74 165.94 ± 41.80
G-CSF 2.75 ± 0.42 1.86 ± 0.22 2.86 ± 0.36 2.25 ± 0.29 1.84 ± 0.49 19.26 ± 16.35
GM-CSF 45.17 ± 8.68 28.58 ± 3.01 36.67 ± 5.53 36.42 ± 9.22 33.90 ± 7.94 50.32 ± 11.00
IFN-g 9.12 ± 0.93 5.87 ± 1.11 * 6.72 ± 0.33 8.56 ± 1.50 6.51 ± 0.95 6.34 ± 1.42
KC 7.78 ± 0.72 6.09 ± 0.33 7.28 ± 0.36 6.09 ± 0.53 6.98 ± 0.88 6.43 ± 0.76
MCP-1 35.94 ± 3.61 28.97 ± 2.42 35.77 ± 3.13 31.84 ± 2.72 31.64 ± 6.68 37.20 ± 6.21
MIP-1a 7.43 ± 1.56 4.67 ± 0.93 5.16 ± 0.88 5.91 ± 1.48 5.21 ± 1.16 21.42 ± 15.96
MIP-1b 86.94 ± 31.45 25.25 ± 11.71 76.01 ± 26.44 77.59 ± 30.44 60.06 ± 24.07 84.33 ± 25.03
Rantes 5.80 ± 0.63 3.66 ± 0.28 3.65 ± 0.20 5.32 ± 0.52 3.80 ± 0.64 5.21 ± 1.95
TNF-a 248.2 ± 53.3 224.0 ± 62.5 273.5 ± 29.9
292206.2 ± 
291931.3 *
230.0 ± 52.2 247.6 ± 31.6
Cytokine
HIPPO 14 DAY
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Frontal Cortex 2 day 
Animal Group 
Active 
Caspase-
3 
Bcl-xl 
Bak 
Mcl-1 
Bak  
Survivin 
1527 CBDP+SARIN 0.11 1.14 3.12 OOR < 
1529 CBDP+SARIN 0.6 0.4 1.25 0.02 
1542 CBDP+SARIN OOR < 0.16 OOR < OOR < 
1547 CBDP+SARIN 0.05 0.33 OOR < OOR < 
8001 CBDP+SARIN 0.32 1.27 6.33 0.47 
1526 CBDP+SARIN+Q-VD 0.08 0.95 0.69 OOR < 
8004 CBDP+SARIN+Q-VD 0.65 0.59 5.6 0.03 
8009 CBDP+SARIN+Q-VD OOR < 0.4 OOR < OOR < 
8022 CBDP+SARIN+Q-VD 0.02 0.38 OOR < OOR < 
8028 CBDP+SARIN+Q-VD 0.07 0.83 1.7 0.01 
8060 CBDP+SARIN+Q-VD OOR < 0.26 OOR < OOR < 
1554 CBDP+SARIN+Q-VE 0.23 0.99 0.08 OOR < 
8010 CBDP+SARIN+Q-VE 0.57 0.31 1.43 0.04 
8011 CBDP+SARIN+Q-VE 0.18 0.93 4.32 0.13 
8074 CBDP+SARIN+Q-VE 0.28 0.92 1.76 0.32 
8084 CBDP+SARIN+Q-VE 0.01 0.24 OOR < OOR < 
8085 CBDP+SARIN+Q-VE 0.17 0.79 0.5 0.02 
 
Table 9: Apoptosis marker analysis data for frontal cortex at day 2. The data represents 
protein concentration in pg/ml obtained by apoptosis marker analysis.  
OOR: Out of range 
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Frontal Cortex 14 day 
Animal Group 
Active 
Caspase-3 
Bcl-xl 
Bak 
Mcl-1 
Bak  
Survivin 
8018 CBDP+SARIN 0.17 0.62 5.64 OOR < 
8021 CBDP+SARIN 0.23 0.49 2.2 OOR < 
8030 CBDP+SARIN 0.31 0.51 5.29 OOR < 
8057 CBDP+SARIN 0.04 0.34 0.42 OOR < 
8078 CBDP+SARIN 0.11 0.46 4.32 OOR < 
8096 CBDP+SARIN 0.17 0.49 4.02 OOR < 
8034 CBDP+SARIN+Q-VD 0.22 0.52 5.72 OOR < 
8035 CBDP+SARIN+Q-VD 0.04 0.46 0.53 OOR < 
8042 CBDP+SARIN+Q-VD 0.04 0.37 0.68 OOR < 
8090 CBDP+SARIN+Q-VD 0.18 0.43 5.38 OOR < 
8046 CBDP+SARIN+Q-VD 0.16 0.65 1.64 OOR < 
1506 CBDP+SARIN+Q-VE 0.15 0.52 1.15 OOR < 
8062 CBDP+SARIN+Q-VE 0.01 0.07 1.29 OOR < 
8064 CBDP+SARIN+Q-VE 0.07 0.25 1.05 OOR < 
8080 CBDP+SARIN+Q-VE 0.15 0.76 5.15 OOR < 
8081 CBDP+SARIN+Q-VE 0.09 0.32 2.37 OOR < 
8086 CBDP+SARIN+Q-VE OOR < 0.07 OOR < OOR < 
 
Table 10: Apoptosis marker analysis data for frontal cortex at day 14. The data 
represents protein concentration in pg/ml obtained by apoptosis marker analysis.  
OOR: Out of range 
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Table 11: List of all the cytokines analyzed using Bio Plex Cytokine kit alongwith their 
functions 
Cytokine
IL-1α; IL-1b
IL-2
IL-3
IL-4
IL-5
IL-6
IL-9
IL-10
IL-12
IL-13
IL-17
Eotaxin
G-CSF
GM-CSF
IFN-γ
KC
MCP-1
MIP-1α
MIP-1b
Rantes
TNF-α
Cytokine involved in systemic inflammation and is a member of a group of cytokines that 
stimulate the acute phase reaction
Central mediator of the physiologic changes induced by allergic inflammation in many tissues
Potent mediator in delayed-type reactions by increasing chemokine 
Recruits eosinophils by inducing their chemotaxis, and therefore, is implicated in allergic 
responses
Stimulates the survival, proliferation, differentiation and function of neutrophil precursors and 
mature neutrophils
Stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and 
monocytes
Ability to inhibit viral replication directly, and most importantly from its immunostimulatory 
and immunomodulatory effects
Hypernociceptive effects of cytokines [TNF-α, keratinocyte-derived chemokine (KC), and IL-
1β] and their participation in carrageenan (Cg)-induced inflammatory hypernociception
Recruits monocytes,memory T cells, and dendritic cells to the sites of inflammation produced 
by either tissue injury or infection
Causes local inflammatory responses in vivo, and induces superoxide production by 
neutrophils in vitro
Macrophage inflammatory protein-1β (MIP-1β) is a CC chemokine with specificity for CCR5 
receptors
Chemotactic cytokine or chemokine. CCL5 is chemotactic for T cells, eosinophils, and 
basophils, and plays an active role in recruiting leukocytes into inflammatory sites
It stimulates the production of interferon-gamma (IFN-γ) and tumor necrosis factor-alpha 
(TNF-α) from T and natural killer (NK) cells, and reduces IL-4 mediated suppression of IFN-
γ. T cells that produce IL-12 have a coreceptor, CD30, which is associated with IL-12 activity
Function
Table 15: Cytokines and their function
Inflammatory; promotes activation, costimulation, and secretion of cytokines and other acute-
phase proteins; pyrogenic
Attracts white cells
Differentiation of multipotent hematopoeitic stem cells into myeloid progenitor cells
Induces differentiation of naive helper T cells (Th0 cells) to Th2 cells
Proliferation and activation; hallmark of Th2 effector cells
Stimulate immune response, e.g. during infection and after trauma, especially burns or other 
tissue damage leading to inflammation
This cytokine stimulates cell proliferation and prevents apoptosis
Cytokine synthesis inhibitory factor (CSIF), is an anti-inflammatory cytokine
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